[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Mar-Med Co\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":286},{"warningLetters":4,"total":285},[5,31,49,71,84,109,123,141,153,165,182,204,225,245,263],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":28,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":30,"medical_device_id":20,"response_letter_date":20},111,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fready-med-730317-06082026\">Ready Med \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Ready Med \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2451 N McMullen Booth Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Clearwater\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33759\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:readymedstaff@gmail.com\"> readymedstaff@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 730317\u003C\u002Fp>\u003Cp>To Ready Med:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of Ready Med’s website, https:\u002F\u002Freadymednow.com, FDA Establishment Identifier (FEI) 3044868483, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The compounded semaglutide and tirzepatide products displayed on your website identify “Ready Med” or “Ready Med Medical Weight Loss Center” on the pictured label, suggesting Ready Med is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“The same active ingredient in Mounjaro® and Zepbound™”\u003C\u002Fli>\u003Cli>“The same active ingredient in Ozempic® and Rybelsus®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>3. Your website claims that the compounded drug products it offers are sourced from an “FDA licensed compounding facility.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&amp;C Act does not establish an \"FDA-approved\" or \"FDA-licensed” designation for pharmacies or outsourcing facilities.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 730317 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003Cbr>\u003Cbr>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&amp;C Act § 503(b) [21 U.S.C. § 353(b)], FD&amp;C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&amp;C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products. Compounded drug products are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing as is required for new drug applications (NDAs) or abbreviated new drug applications (ANDAs).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nReady Med\n\n2451 N McMullen Booth Rd\n\nClearwater, FL 33759\n\nUnited States\n\nreadymedstaff@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 730317\nTo Ready Med:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of Ready Med’s website, https:\u002F\u002Freadymednow.com, FDA Establishment Identifier (FEI) 3044868483, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The compounded semaglutide and tirzepatide products displayed on your website identify “Ready Med” or “Ready Med Medical Weight Loss Center” on the pictured label, suggesting Ready Med is the compounder of those drugs when in fact it is not.2\n2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“The same active ingredient in Mounjaro® and Zepbound™”\n“The same active ingredient in Ozempic® and Rybelsus®”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\n3. Your website claims that the compounded drug products it offers are sourced from an “FDA licensed compounding facility.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an \"FDA-approved\" or \"FDA-licensed” designation for pharmacies or outsourcing facilities.3 Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 730317 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\n\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&C Act § 503(b) [21 U.S.C. § 353(b)], FD&C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\n3 While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products. Compounded drug products are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing as is required for new drug applications (NDAs) or abbreviated new drug applications (ANDAs).","Ready Med","ready-med-730317-06082026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fready-med-730317-06082026","2026-10-26T08:09:47.703238+00:00","Warning Letter","Issued","2026-06-16","730317","Drugs","2026-08-19T04:36:37.888+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":20,"letter_url":43,"updated_at":44,"action_type":23,"case_status":24,"posted_date":45,"marcs_cms_no":46,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":47,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":48,"medical_device_id":20,"response_letter_date":20},650,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcanada-med-stop-716517-09092025\">Canada Med Stop\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Canada Med Stop\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>PO BOX 75026 Main Street South PO\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vancouver\u003C\u002Fspan> \u003Cspan>BC\u003C\u002Fspan> \u003Cspan>V5X 4V7\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@canadamedstop.com\"> info@canadamedstop.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Canada Med Stop:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.canadamedstop.com in August 2025 and has observed that your website offers compounded semaglutide drug products.\u003Ca id=\"footnoteref1_te8ha74\" href=\"#footnote1_te8ha74\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cp>• &nbsp;“The same active ingredient in branded weight loss medications.”\u003Cbr>• “FDA-Approved Medication”\u003Cbr>• “GENERIC”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_90odni9\" href=\"#footnote2_90odni9\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D. Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_te8ha74\">\u003Ca href=\"#footnoteref1_te8ha74\">1\u003C\u002Fa>The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_90odni9\">\u003Ca href=\"#footnoteref2_90odni9\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nCanada Med Stop\n\nPO BOX 75026 Main Street South PO\n\nVancouver BC V5X 4V7\n\nCanada\n\ninfo@canadamedstop.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nCanada Med Stop:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.canadamedstop.com in August 2025 and has observed that your website offers compounded semaglutide drug products.1 As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide products appear on your website:\n• “The same active ingredient in branded weight loss medications.”\n• “FDA-Approved Medication”\n• “GENERIC”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nGeorge Tidmarsh, M.D., Ph.D. Director\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Canada Med Stop","canada-med-stop-716517-09092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcanada-med-stop-716517-09092025","2026-10-26T08:08:10.68794+00:00","2025-09-16","716517","2026-08-19T16:19:42.969+00:00","2025-09-09",{"id":50,"raw":51,"subject":56,"body_html":57,"body_text":58,"firm_name":59,"letter_id":60,"created_at":61,"fei_number":20,"letter_url":62,"updated_at":63,"action_type":23,"case_status":24,"posted_date":64,"marcs_cms_no":65,"product_type":66,"closeout_date":20,"issuing_office":55,"recipient_name":67,"body_fetched_at":68,"delivery_method":69,"recipient_title":20,"reference_number":20,"action_taken_date":70,"medical_device_id":20,"response_letter_date":20},2418,[52,53,54,55,56,13,13,13],"\u003Ctime datetime=\"2022-09-27T13:20:00Z\">09\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-15T04:00:00Z\">09\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmed-pen-concepts-llc-632974-09152022\">Med Pen Concepts, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Amy J. Aarons\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Med Pen Concepts, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 W Cummings Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Woburn\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 632974\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 15, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Aarons:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 800 W Cummings Park, Woburn, MA 01801 conducted on five dates from April 5, 2022, through April 13, 2022, investigators from the United States Food and Drug Administration (FDA) observed that your firm is a manufacturer of “Plasma MD” and “Plasma +” branded products intended to improve the appearance of skin by stimulating the production of collagen and other proteins. Under section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from Scott Blood, Director of Regulatory Services, MEDIcept, Inc., on behalf of your firm, dated April 28, 2022, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below as appropriate in relation to the noted concerns.\u003C\u002Fp>\n\n\u003Cp>As an initial matter, we note that evidence collected during the inspection, including product packaging and labels, user manuals, and brochures, and product labeling on your firm’s website at http:\u002F\u002FPlasmaConcepts.com, reveal that these products are devices within the meaning of the Act. For example, a review of your firm’s website, http:\u002F\u002FPlasmaConcepts.com (last accessed on June 09, 2022 and July 01, 2022), revealed the following claims:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“This handheld device looks like a pen, but it’s actually a state-of-the-art tool that uses plasma, a naturally occurring ionized gas, to combat wrinkles and tighten sagging skin on the face and body.”\u003C\u002Fli>\n\t\u003Cli>“PlasmaMD works to improve skin by stimulating the production of collagen and elastin, the proteins that keep skin firm and supple.”\u003C\u002Fli>\n\t\u003Cli>“This treatment is also called fibroblast therapy or ‘fibroblasting,’ because it stimulates the fibroblast cells that produce this new collagen and elastin.”\u003C\u002Fli>\n\t\u003Cli>“[I]t works by emitting plasma energy, which reacts with the naturally occurring nitrogen molecules creates an energetic burst in the shape of an arc, creating a microinjury in the top layer of skin as well as heating up the dermis, where it causes collagen fibers to contract.\"\u003C\u002Fli>\n\t\u003Cli>“Many of today’s physicians are using PlasmaMD to target the eye area, including the upper eyelids, lower eyelids and crow’s feet.”\u003C\u002Fli>\n\t\u003Cli>“Some physicians are using PlasmaMD as a non-surgical alternative to traditional blepharoplasty, performing what they refer to as ‘non-surgical eyelid lifts.’”\u003C\u002Fli>\n\t\u003Cli>“PlasmaMD creates controlled micro-injuries to the skin, which results in some immediate firming. These micro-injuries stimulate the body’s natural wound healing response, triggering the growth of new collagen and elastin in the weeks and months following treatment.”\u003C\u002Fli>\n\t\u003Cli>“PlasmaMD has low risk of side effects and minimal downtime when compared to more invasive surgical options.”\u003C\u002Fli>\n\t\u003Cli>“These controlled microinjuries promote a long-term firming, tightening and smoothing through the skin’s own natural healing response.”\u003C\u002Fli>\n\t\u003Cli>“PlasmaMD’s unique plasma arc precision reduces unwanted and unnecessary damage to the skin surrounding the treatment area, reducing downtime and risk.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Based on these claims, among other things, the products listed are intended to affect the structure or any function of the body (e.g., tightening and smoothing skin; lessening the appearance of lines or wrinkles) and are therefore devices within the meaning of the Act. Indeed, your firm has acknowledged the same, with Mr. Blood writing that, on or around June 1, 2021, “it became apparent that the device, marketing [sic] with medical device claims, would require some form of regulatory support for premarket notification,” and that “it became apparent that the devices are indeed considered medical devices” subject to medical device regulations.\u003C\u002Fp>\n\n\u003Cp>FDA’s concerns with respect to these devices include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Adulteration under Section 501(h) for Failure to Conform with Current Good Manufacturing Practice Requirements\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for the identification, documentation, validation, or (where appropriate) verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i).\u003Cbr>\nSpecifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s design change procedure, QOP-73-03, Control of Design Changes (Rev. A; Effective Date: 7\u002F19\u002F2019), was not followed when your firm-initiated changes to the tips used with the plasma pens. These changes include changing the tip from sterile to non-sterile and a change to a new tip manufacturer from a different country.\u003C\u002Fp>\n\n\u003Cp>Further, your firm’s activities involving this design change to include identification, documentation, validation, or (where appropriate) verification, review, and approval of the change were not documented. This documentation is required in section 1.1 of your QOP-73-03 procedure in which it states: “Design changes are initiated, reviewed and implemented in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Change Control module using electronic form EF-390-1 Change Request”.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitments to perform several corrective actions to include initiation of a CAPA to address this 483 observation, completing a design change request to document the tip design change, conduction of a risk assessment of the tip change, implementation of the tip change upon approval, completion of a document change request, updates to the design history file, and management of inventory per risk assessment results and actions from design change request. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 21 CFR § 820.100(a). Specifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s CAPA procedure, QOP-85-03, Corrective and Preventive Action (Rev. A; effective date: 8\u002F20\u002F2019), includes the following requirement in section 3.1: “CAPAs are initiated and processed in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> CAPA module using electronic form EF-130-1 Corrective and Preventive Action”. Your firm initiated a change to improve the power control of your plasma devices. This change was not conducted or documented in accordance with your CAPA procedure.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitments to initiate a CAPA to address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> distributed devices, conduct a risk assessment for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> distributed devices, and to manage inventory disposition per risk assessment and CAPA actions. However, your response does not address if you will be initiating a corrective and preventive action for your firm’s decision to change to an improved power control for the plasma devices. Further, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of the promised corrective actions as they become available.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198.\u003Cbr>\nSpecifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s complaint handling procedure, Complaints, (QOP-85-02; Rev. B; effective date 11\u002F15\u002F2019), includes the following requirement in section 1.2: “Complaints are recorded by Customer Service. in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Complaints module using electronic form EF-190-1 Complaint”. Your firm has received 17 complaints since September of 2019 and did not utilize electronic form EF-190-1 for the documentation of complaints. Rather your firm utilized a “Credit Memo” document (no form number or effective date) for complaint files. For these seventeen complaint files created since the establishment of your procedure, some or all the following information was not routinely recorded as required by 21 CFR § 820.198(e):\u003C\u002Fp>\n\n\u003Cp>(1) The name of the device;\u003Cbr>\n(2) The date the complaint was received;\u003Cbr>\n(3) Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used;\u003Cbr>\n(4) The name, address, and phone number of the complainant;\u003Cbr>\n(5) The nature and details of the complaint;\u003Cbr>\n(6) The dates and results of the investigation;\u003Cbr>\n(7) Any corrective action taken; and\u003Cbr>\n(8) Any reply to the complainant.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitments to update procedure QOP-85-02, reassess and update all 17 complaints taken since September 2019 per your procedure once updated, and to train your quality complaint unit on the updated complaint procedure and record-keeping processes. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements. Acceptance or rejection shall be documented, as required by 21 CFR § 820.80(b). Specifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s procedures, QOP-74-02, Purchasing (Rev. B; Effective Date: 11\u002F15\u002F2019) &amp; QOP-74-03, Verification of Purchased Product (Rev. A; Effective Date: 7\u002F25\u002F2019) were not followed in that activities surrounding acceptance of devices were not documented showing that your firm is inspecting, testing, or otherwise verifying that devices received from contract manufacturers conform to specified requirements.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitments to perform corrective actions to include initiation of a CAPA to address this 483 observation and the retrospective assessment and acceptance or all devices and tips in inventory. However, none of these promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\u003C\u002Fp>\n\n\u003Cp>5. Failure to maintain device history records (DHR's), as required by 21 CFR § 820.184.\u003Cbr>\nSpecifically,\u003C\u002Fp>\n\n\u003Cp>Your firm does not maintain device history records (DHR’s) for the plasma devices received from contract manufacturers which are then further packaged with instructions for use (IFUs) and other products as part of a convenience kits that is then distributed. DHR’s have not been created to include or refer to location of, the following information: (a) The dates of manufacture; (b) The quantity manufactured; (c) The quantity released for distribution; (d) The acceptance records which demonstrate the device is manufactured in accordance with the DMR; (e) The primary identification label and labeling used for each production unit; and (f) Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plasma devices your firm has sold since the beginning of your firm’s sales of these products in September 2019.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitments to perform corrective actions to include initiation of a CAPA to address this 483 observation, updating your associated procedures and forms, and the retrospective performance of DHR’s for all devices. However, none of these promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\u003C\u002Fp>\n\n\u003Cp>6. Failure to adequately establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system. The dates and results of quality audits and reaudits shall be documented, as required by 21 CFR § 820.22. Specifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality audit procedure, QOP-82-02, Internal Quality Audits (Rev. A; Effective Date: 8\u002F20\u002F2019), covers the process for conducting internal audits of your quality system to include the requirement in section 1.2 that states: “Each quality system process is audited at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. During the inspection, the Chief Strategy Officer stated that one internal audit had been performed since operations for the plasma devices began in September 2019. Further, your Chief Strategy Officer stated this audit was not documented.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitments to perform several corrective actions to include initiation of a CAPA to address this 483 observation, the development and scheduling of an internal audit plan, assignment of internal auditors, and conduction of an internal audit. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\u003C\u002Fp>\n\n\u003Cp>7. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency according to established procedures to ensure that the quality system satisfies the requirements of this part and the manufacturer's established quality policy and objectives. The dates and results of quality system reviews shall be documented, as required by 21 CFR § 820.20(c). Specifically,\u003C\u002Fp>\n\n\u003Cp>Your firm’s management review procedure, QOP-56-01, Management Review (Rev. A; Effective Date: 7\u002F9\u002F2019), states in section 1.2 that management reviews are conducted at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm has not conducted a management review since medical device operations began in 2019.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitments to perform several corrective actions to include initiation of a CAPA to address this 483 observation, conduction of a Management Review for year 2022 and the scheduling of a subsequent 2023 Management Review. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Adulteration under Section 501(f)(1)(B) for Failure to Have an Approved PMA or IDE\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the Plasma MD and Plasma + devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Misbranding under Section 502(o) for Failure to Submit a 510(k)\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>The notification required by section 510(k) of the Act is not required for a device for which a PMA is pending before the agency. 21 CFR 807.81(b)(1). The kind of information that your firm could submit in order to obtain approval or clearance for the devices is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and respond as appropriate.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Misbranding under Section 502(c) for Failure to Have Compliant Labeling\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Plasma MD and Plasma + devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Misbranding under Section 502(t)(2) for Failure to Submit Required Information to GUDID\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition, your devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\n\n\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\n\n\u003Cp>* * *\u003C\u002Fp>\n\n\u003Cp>We request that your firm immediately cease any activities that result in the misbranding or adulteration of the devices, such as their commercial distribution as discussed above.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Your firm should take prompt action to correct any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We ask that you please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all concerns included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 632974 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer, at 410-779-5134 or sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to provide an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s devices, manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies, and take prompt actions to correct any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, MD, MBA, FACS\u003Cbr>\nDirector\u003Cbr>\nOHT 4: Office of Surgery and Infection Control\u003Cbr>\n&nbsp; &nbsp; Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\n&nbsp; &nbsp; Operations\u003Cbr>\nDivision 1 - East\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nBrendan J. Aarons, Chief Strategy Officer (CSO), Med Pen Concepts, LLC\u003Cbr>\nDonald W. Shooter, Chief Executive Officer (CEO), Med Pen Concepts, LLC\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAmy J. Aarons\n\nRecipient Title\n\nPresident\n\nMed Pen Concepts, LLC\n\n800 W Cummings Park\n\nWoburn, MA 01801\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 632974\n\nSeptember 15, 2022\n\nDear Ms. Aarons:\n\nDuring an inspection of your firm located at 800 W Cummings Park, Woburn, MA 01801 conducted on five dates from April 5, 2022, through April 13, 2022, investigators from the United States Food and Drug Administration (FDA) observed that your firm is a manufacturer of “Plasma MD” and “Plasma +” branded products intended to improve the appearance of skin by stimulating the production of collagen and other proteins. Under section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received a response from Scott Blood, Director of Regulatory Services, MEDIcept, Inc., on behalf of your firm, dated April 28, 2022, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below as appropriate in relation to the noted concerns.\n\nAs an initial matter, we note that evidence collected during the inspection, including product packaging and labels, user manuals, and brochures, and product labeling on your firm’s website at http:\u002F\u002FPlasmaConcepts.com, reveal that these products are devices within the meaning of the Act. For example, a review of your firm’s website, http:\u002F\u002FPlasmaConcepts.com (last accessed on June 09, 2022 and July 01, 2022), revealed the following claims:\n\n“This handheld device looks like a pen, but it’s actually a state-of-the-art tool that uses plasma, a naturally occurring ionized gas, to combat wrinkles and tighten sagging skin on the face and body.”\n\n“PlasmaMD works to improve skin by stimulating the production of collagen and elastin, the proteins that keep skin firm and supple.”\n\n“This treatment is also called fibroblast therapy or ‘fibroblasting,’ because it stimulates the fibroblast cells that produce this new collagen and elastin.”\n\n“[I]t works by emitting plasma energy, which reacts with the naturally occurring nitrogen molecules creates an energetic burst in the shape of an arc, creating a microinjury in the top layer of skin as well as heating up the dermis, where it causes collagen fibers to contract.\"\n\n“Many of today’s physicians are using PlasmaMD to target the eye area, including the upper eyelids, lower eyelids and crow’s feet.”\n\n“Some physicians are using PlasmaMD as a non-surgical alternative to traditional blepharoplasty, performing what they refer to as ‘non-surgical eyelid lifts.’”\n\n“PlasmaMD creates controlled micro-injuries to the skin, which results in some immediate firming. These micro-injuries stimulate the body’s natural wound healing response, triggering the growth of new collagen and elastin in the weeks and months following treatment.”\n\n“PlasmaMD has low risk of side effects and minimal downtime when compared to more invasive surgical options.”\n\n“These controlled microinjuries promote a long-term firming, tightening and smoothing through the skin’s own natural healing response.”\n\n“PlasmaMD’s unique plasma arc precision reduces unwanted and unnecessary damage to the skin surrounding the treatment area, reducing downtime and risk.”\n\nBased on these claims, among other things, the products listed are intended to affect the structure or any function of the body (e.g., tightening and smoothing skin; lessening the appearance of lines or wrinkles) and are therefore devices within the meaning of the Act. Indeed, your firm has acknowledged the same, with Mr. Blood writing that, on or around June 1, 2021, “it became apparent that the device, marketing [sic] with medical device claims, would require some form of regulatory support for premarket notification,” and that “it became apparent that the devices are indeed considered medical devices” subject to medical device regulations.\n\nFDA’s concerns with respect to these devices include, but are not limited to, the following:\n\nAdulteration under Section 501(h) for Failure to Conform with Current Good Manufacturing Practice Requirements\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\n1. Failure to adequately establish and maintain procedures for the identification, documentation, validation, or (where appropriate) verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i).\n\nSpecifically,\n\nYour firm’s design change procedure, QOP-73-03, Control of Design Changes (Rev. A; Effective Date: 7\u002F19\u002F2019), was not followed when your firm-initiated changes to the tips used with the plasma pens. These changes include changing the tip from sterile to non-sterile and a change to a new tip manufacturer from a different country.\n\nFurther, your firm’s activities involving this design change to include identification, documentation, validation, or (where appropriate) verification, review, and approval of the change were not documented. This documentation is required in section 1.1 of your QOP-73-03 procedure in which it states: “Design changes are initiated, reviewed and implemented in (b)(4) Change Control module using electronic form EF-390-1 Change Request”.\n\nWe acknowledge your commitments to perform several corrective actions to include initiation of a CAPA to address this 483 observation, completing a design change request to document the tip design change, conduction of a risk assessment of the tip change, implementation of the tip change upon approval, completion of a document change request, updates to the design history file, and management of inventory per risk assessment results and actions from design change request. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 21 CFR § 820.100(a). Specifically,\n\nYour firm’s CAPA procedure, QOP-85-03, Corrective and Preventive Action (Rev. A; effective date: 8\u002F20\u002F2019), includes the following requirement in section 3.1: “CAPAs are initiated and processed in the (b)(4) CAPA module using electronic form EF-130-1 Corrective and Preventive Action”. Your firm initiated a change to improve the power control of your plasma devices. This change was not conducted or documented in accordance with your CAPA procedure.\n\nWe acknowledge your commitments to initiate a CAPA to address the (b)(4) distributed devices, conduct a risk assessment for the (b)(4) distributed devices, and to manage inventory disposition per risk assessment and CAPA actions. However, your response does not address if you will be initiating a corrective and preventive action for your firm’s decision to change to an improved power control for the plasma devices. Further, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of the promised corrective actions as they become available.\n\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198.\n\nSpecifically,\n\nYour firm’s complaint handling procedure, Complaints, (QOP-85-02; Rev. B; effective date 11\u002F15\u002F2019), includes the following requirement in section 1.2: “Complaints are recorded by Customer Service. in (b)(4) Complaints module using electronic form EF-190-1 Complaint”. Your firm has received 17 complaints since September of 2019 and did not utilize electronic form EF-190-1 for the documentation of complaints. Rather your firm utilized a “Credit Memo” document (no form number or effective date) for complaint files. For these seventeen complaint files created since the establishment of your procedure, some or all the following information was not routinely recorded as required by 21 CFR § 820.198(e):\n\n(1) The name of the device;\n\n(2) The date the complaint was received;\n\n(3) Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used;\n\n(4) The name, address, and phone number of the complainant;\n\n(5) The nature and details of the complaint;\n\n(6) The dates and results of the investigation;\n\n(7) Any corrective action taken; and\n\n(8) Any reply to the complainant.\n\nWe acknowledge your commitments to update procedure QOP-85-02, reassess and update all 17 complaints taken since September 2019 per your procedure once updated, and to train your quality complaint unit on the updated complaint procedure and record-keeping processes. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\n\n4. Failure to adequately establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements. Acceptance or rejection shall be documented, as required by 21 CFR § 820.80(b). Specifically,\n\nYour firm’s procedures, QOP-74-02, Purchasing (Rev. B; Effective Date: 11\u002F15\u002F2019) & QOP-74-03, Verification of Purchased Product (Rev. A; Effective Date: 7\u002F25\u002F2019) were not followed in that activities surrounding acceptance of devices were not documented showing that your firm is inspecting, testing, or otherwise verifying that devices received from contract manufacturers conform to specified requirements.\n\nWe acknowledge your commitments to perform corrective actions to include initiation of a CAPA to address this 483 observation and the retrospective assessment and acceptance or all devices and tips in inventory. However, none of these promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\n\n5. Failure to maintain device history records (DHR's), as required by 21 CFR § 820.184.\n\nSpecifically,\n\nYour firm does not maintain device history records (DHR’s) for the plasma devices received from contract manufacturers which are then further packaged with instructions for use (IFUs) and other products as part of a convenience kits that is then distributed. DHR’s have not been created to include or refer to location of, the following information: (a) The dates of manufacture; (b) The quantity manufactured; (c) The quantity released for distribution; (d) The acceptance records which demonstrate the device is manufactured in accordance with the DMR; (e) The primary identification label and labeling used for each production unit; and (f) Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used for the (b)(4) plasma devices your firm has sold since the beginning of your firm’s sales of these products in September 2019.\n\nWe acknowledge your commitments to perform corrective actions to include initiation of a CAPA to address this 483 observation, updating your associated procedures and forms, and the retrospective performance of DHR’s for all devices. However, none of these promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\n\n6. Failure to adequately establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system. The dates and results of quality audits and reaudits shall be documented, as required by 21 CFR § 820.22. Specifically,\n\nYour firm’s quality audit procedure, QOP-82-02, Internal Quality Audits (Rev. A; Effective Date: 8\u002F20\u002F2019), covers the process for conducting internal audits of your quality system to include the requirement in section 1.2 that states: “Each quality system process is audited at least (b)(4)”. During the inspection, the Chief Strategy Officer stated that one internal audit had been performed since operations for the plasma devices began in September 2019. Further, your Chief Strategy Officer stated this audit was not documented.\n\nWe acknowledge your commitments to perform several corrective actions to include initiation of a CAPA to address this 483 observation, the development and scheduling of an internal audit plan, assignment of internal auditors, and conduction of an internal audit. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\n\n7. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency according to established procedures to ensure that the quality system satisfies the requirements of this part and the manufacturer's established quality policy and objectives. The dates and results of quality system reviews shall be documented, as required by 21 CFR § 820.20(c). Specifically,\n\nYour firm’s management review procedure, QOP-56-01, Management Review (Rev. A; Effective Date: 7\u002F9\u002F2019), states in section 1.2 that management reviews are conducted at least (b)(4). Your firm has not conducted a management review since medical device operations began in 2019.\n\nWe acknowledge your commitments to perform several corrective actions to include initiation of a CAPA to address this 483 observation, conduction of a Management Review for year 2022 and the scheduling of a subsequent 2023 Management Review. However, none of your promised actions have been completed. In your response, provide any timeframe updates for the activities promised as well as the results of your promised corrective actions as they become available.\n\nAdulteration under Section 501(f)(1)(B) for Failure to Have an Approved PMA or IDE\n\nOur inspection also revealed that the Plasma MD and Plasma + devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nMisbranding under Section 502(o) for Failure to Submit a 510(k)\n\nThe devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nThe notification required by section 510(k) of the Act is not required for a device for which a PMA is pending before the agency. 21 CFR 807.81(b)(1). The kind of information that your firm could submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\n\nMisbranding under Section 502(c) for Failure to Have Compliant Labeling\n\nThe inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Plasma MD and Plasma + devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\n\nMisbranding under Section 502(t)(2) for Failure to Submit Required Information to GUDID\n\nIn addition, your devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\n\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\n\n* * *\n\nWe request that your firm immediately cease any activities that result in the misbranding or adulteration of the devices, such as their commercial distribution as discussed above.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Your firm should take prompt action to correct any violations.\n\nFailure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nWe ask that you please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all concerns included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 632974 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer, at 410-779-5134 or sean.moynihan@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to provide an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s devices, manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies, and take prompt actions to correct any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS\n\nDirector\n\nOHT 4: Office of Surgery and Infection Control\n\nDevices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations\n\nDivision 1 - East\n\nCc:\n\nBrendan J. Aarons, Chief Strategy Officer (CSO), Med Pen Concepts, LLC\n\nDonald W. Shooter, Chief Executive Officer (CEO), Med Pen Concepts, LLC","Med Pen Concepts, LLC","med-pen-concepts-llc-632974-09152022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmed-pen-concepts-llc-632974-09152022","2026-10-26T08:09:22.543565+00:00","2022-09-27","632974","Medical Devices","Amy J. Aarons","2026-08-20T01:32:17.888+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-09-15",{"id":72,"raw":73,"subject":37,"body_html":75,"body_text":76,"firm_name":77,"letter_id":78,"created_at":42,"fei_number":20,"letter_url":79,"updated_at":80,"action_type":23,"case_status":24,"posted_date":45,"marcs_cms_no":81,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":82,"delivery_method":83,"recipient_title":20,"reference_number":20,"action_taken_date":48,"medical_device_id":20,"response_letter_date":20},654,[34,35,74,11,37,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvigorate-med-spa-715872-09092025\">Invigorate Med Spa\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Invigorate Med Spa\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8199 McKnight Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pittsburg\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>15237\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@invigoratemedspa.com\"> info@invigoratemedspa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Invigorate Med Spa:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Finvigoratemedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Semaglutide (Wegovy)”\u003C\u002Fli>\u003Cli>“Tirzepatide\u002FB12 (Mounjaro)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nInvigorate Med Spa\n\n8199 McKnight Rd\n\nPittsburg, PA 15237\n\nUnited States\n\ninfo@invigoratemedspa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nInvigorate Med Spa:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Finvigoratemedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.1 As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Semaglutide (Wegovy)”\n“Tirzepatide\u002FB12 (Mounjaro)”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Invigorate Med Spa","invigorate-med-spa-715872-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvigorate-med-spa-715872-09092025","2026-10-26T08:09:00.570999+00:00","715872","2026-08-19T16:22:46.151+00:00","Via Electronic Mail - Delivery and Read Receipt Requested",{"id":85,"raw":86,"subject":93,"body_html":94,"body_text":95,"firm_name":96,"letter_id":97,"created_at":98,"fei_number":20,"letter_url":99,"updated_at":100,"action_type":23,"case_status":101,"posted_date":102,"marcs_cms_no":103,"product_type":27,"closeout_date":104,"issuing_office":90,"recipient_name":105,"body_fetched_at":106,"delivery_method":107,"recipient_title":20,"reference_number":20,"action_taken_date":108,"medical_device_id":20,"response_letter_date":20},2747,[87,88,89,90,91,13,92,13],"\u003Ctime datetime=\"2022-04-12T13:20:00Z\">04\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-18T04:00:00Z\">03\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmed-shop-total-care-inc-628182-03182022\">Med Shop Total Care, Inc.\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","Compounding Pharmacy\u002FAdulterated Drug Products ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmed-shop-total-care-inc-628182-10112023\">\u003Ctime datetime=\"2023-10-24T04:00:00Z\">10\u002F24\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jennifer Yoakum\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Owner and Pharmacist-In-Charge\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Med Shop Total Care, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>470 E Loop 281\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Longview\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75605-7939\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 18, 2022\u003C\u002Fp>\n\n\u003Cp>Case #628182\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Ms. Yoakum:\u003C\u002Fp>\n\n\u003Cp>From July 7, 2021, to July 27, 2021, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Med Shop Total Care, Inc., located at 470 E Loop 281, Longview, TX 75605. During the inspection, the investigator noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on July 27, 2021. FDA acknowledges receipt of your facility’s response, dated August 17, 2021. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Cbr>\n\u003Cbr>\n\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed:\u003C\u002Fp>\n\n\u003Cp>1. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>2. An operator placed their gloved hands outside the ISO 5 aseptic processing area to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to establish an adequate contact time for a disinfecting agent used in your aseptic processing areas.\u003C\u002Fp>\n\n\u003Cp>4. A brownish residue on the protective screen of the HEPA filter within your ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Regarding your response to Observation 1, your response is inadequate. Any microbial contamination in the ISO 5 area is considered an insanitary condition. Any microbial contamination within the ISO 5 area is a serious concern and upon recovery, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could be affected.\u003C\u002Fp>\n\n\u003Cp>In addition, in response to Observation 7, we acknowledge your immediate recall upon notification from your third-party testing laboratory of a sterility failure for a bulk intermediate. We also acknowledge your statement that all recovered prescriptions that contained the lot in question “…were tested for sterility and test results showed that all were sterile.” Please note, microbial contamination, when present, is not uniformly distributed within a batch; therefore, it may not be identified in a sterility test. Compounding facilities producing drug products intended to be sterile under insanitary conditions should not rely upon or cite a passing sterility test result as an indication of product sterility.\u003C\u002Fp>\n\n\u003Cp>2. In response to Observation 5, we acknowledge your statement, “In an effort to reduce movement in and out of the hood, we are currently testing computer keyboards that are designed for clean room areas, and which may be kept inside the hood, so that logging information can be conducted during our processing.” However, your response is inadequate as it does not indicate a timeframe for implementation or any appropriate interim actions to address this concern.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (Case #628182). Please electronically submit your signed reply on your firm’s letterhead to ORA PHARM2 Acting DCB at orapharm2actingdcb@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>cc: VIA ELECTRONIC MAIL\u003Cbr>\nTim Tucker, Pharm.D., Executive Director\u002FSecretary\u003Cbr>\nTexas State Board of Pharmacy\u003Cbr>\n333 Guadalupe, Suite #3-500\u003Cbr>\nAustin, Texas 78701\u003Cbr>\ntim.tucker@pharmacy.texas.gov\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJennifer Yoakum\n\nRecipient Title\n\nCo-Owner and Pharmacist-In-Charge\n\nMed Shop Total Care, Inc.\n\n470 E Loop 281\n\nLongview, TX 75605-7939\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nMarch 18, 2022\n\nCase #628182\n\nWARNING LETTER\n\nDear Ms. Yoakum:\n\nFrom July 7, 2021, to July 27, 2021, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Med Shop Total Care, Inc., located at 470 E Loop 281, Longview, TX 75605. During the inspection, the investigator noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on July 27, 2021. FDA acknowledges receipt of your facility’s response, dated August 17, 2021. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed:\n\n1. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\n\n2. An operator placed their gloved hands outside the ISO 5 aseptic processing area to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\n\n3. Your firm failed to establish an adequate contact time for a disinfecting agent used in your aseptic processing areas.\n\n4. A brownish residue on the protective screen of the HEPA filter within your ISO 5 aseptic processing area.\n\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483.\n\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, the following corrective actions appear deficient:\n\n1. Regarding your response to Observation 1, your response is inadequate. Any microbial contamination in the ISO 5 area is considered an insanitary condition. Any microbial contamination within the ISO 5 area is a serious concern and upon recovery, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could be affected.\n\nIn addition, in response to Observation 7, we acknowledge your immediate recall upon notification from your third-party testing laboratory of a sterility failure for a bulk intermediate. We also acknowledge your statement that all recovered prescriptions that contained the lot in question “…were tested for sterility and test results showed that all were sterile.” Please note, microbial contamination, when present, is not uniformly distributed within a batch; therefore, it may not be identified in a sterility test. Compounding facilities producing drug products intended to be sterile under insanitary conditions should not rely upon or cite a passing sterility test result as an indication of product sterility.\n\n2. In response to Observation 5, we acknowledge your statement, “In an effort to reduce movement in and out of the hood, we are currently testing computer keyboards that are designed for clean room areas, and which may be kept inside the hood, so that logging information can be conducted during our processing.” However, your response is inadequate as it does not indicate a timeframe for implementation or any appropriate interim actions to address this concern.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\n\nYour written notification should refer to the Warning Letter Number above (Case #628182). Please electronically submit your signed reply on your firm’s letterhead to ORA PHARM2 Acting DCB at orapharm2actingdcb@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\ncc: VIA ELECTRONIC MAIL\n\nTim Tucker, Pharm.D., Executive Director\u002FSecretary\n\nTexas State Board of Pharmacy\n\n333 Guadalupe, Suite #3-500\n\nAustin, Texas 78701\n\ntim.tucker@pharmacy.texas.gov","Med Shop Total Care, Inc.","med-shop-total-care-inc-628182-03182022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmed-shop-total-care-inc-628182-03182022","2026-10-26T08:09:22.620097+00:00","Closed Out","2022-04-12","628182","2023-10-24","Jennifer Yoakum","2026-08-20T02:01:16.005+00:00","VIA Electronic Mail","2022-03-18",{"id":110,"raw":111,"subject":14,"body_html":114,"body_text":115,"firm_name":116,"letter_id":117,"created_at":118,"fei_number":20,"letter_url":119,"updated_at":120,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":121,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":122,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":30,"medical_device_id":20,"response_letter_date":20},3696,[8,9,112,11,113,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglow-medispa-llc-dba-mint-med-730390-06082026\">Glow Medispa, LLC dba Mint Med\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Glow Medispa, LLC dba Mint Med\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8833 Chapel Square Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cincinnati\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45249\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@mintmed.com\"> help@mintmed.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 730390\u003C\u002Fp>\u003Cp>To Mint Med:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of Mint Med’s website, https:\u002F\u002Fmintmed.com, FDA Establishment Identifier (FEI) 3044896930, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The compounded semaglutide and tirzepatide products displayed on your website identify “Mint Med” on the pictured label, suggesting Mint Med is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 730390 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&amp;C Act § 503(b) [21 U.S.C. § 353(b)], FD&amp;C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nGlow Medispa, LLC dba Mint Med\n\n8833 Chapel Square Dr.\n\nCincinnati, OH 45249\n\nUnited States\n\nhelp@mintmed.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 730390\nTo Mint Med:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of Mint Med’s website, https:\u002F\u002Fmintmed.com, FDA Establishment Identifier (FEI) 3044896930, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The compounded semaglutide and tirzepatide products displayed on your website identify “Mint Med” on the pictured label, suggesting Mint Med is the compounder of those drugs when in fact it is not.2\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 730390 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n__________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&C Act § 503(b) [21 U.S.C. § 353(b)], FD&C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].","Glow Medispa, LLC dba Mint Med","glow-medispa-llc-dba-mint-med-730390-06082026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglow-medispa-llc-dba-mint-med-730390-06082026","2026-10-26T08:08:47.0873+00:00","730390","2026-08-19T04:35:14.604+00:00",{"id":124,"raw":125,"subject":130,"body_html":131,"body_text":132,"firm_name":133,"letter_id":134,"created_at":19,"fei_number":20,"letter_url":135,"updated_at":136,"action_type":23,"case_status":24,"posted_date":137,"marcs_cms_no":138,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":139,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":140,"medical_device_id":20,"response_letter_date":20},53,[126,127,128,11,129,13,13,13],"\u003Ctime datetime=\"2026-07-07T04:00:00Z\">07\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-23T04:00:00Z\">06\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmed-shop-inc-wwwmedshopinccom-725157-06232026\">Med Shop Inc \u002F www.medshopinc.com\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Med Shop Inc \u002F www.medshopinc.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Netherlands\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@medshopinc.com\"> info@medshopinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 23, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: MARCS-CMS 725157\u003C\u002Fp>\u003Cp>To Med Shop Inc:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.medshopinc.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, FDA has observed that www.medshopinc.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\u003C\u002Fp>\u003Cp>There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.\u003C\u002Fp>\u003Cp>Accordingly, FDA requests that www.medshopinc.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website www.medshopinc.com, FDA Establishment Identifier (FEI) 3043544193, on February 27, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On your website at internet address www.medshopinc.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 331(a), 331(d), 352(f)(1), 353(b)(1), and 355(a)).\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>Unapproved New Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.medshopinc.com are drugs within the meaning of section 201(g) of the FD&amp;C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>You failed to obtain approved applications pursuant to section 505 of the FD&amp;C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved ketamine drug product you offer for sale on www.medshopinc.com is esketamine marketed as \"Ketamine Nasal Spray.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Ketamine Nasal Spray is a powerful treatment option designed for individuals suffering from treatment-resistant depression and chronic pain. Administered as a nasal spray, it offers rapid relief by acting on NMDA receptors in the brain.\"\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of ketamine drug products on the market in the United States, there is no approved drug application pursuant to section 505 of the FD&amp;C Act in effect for \"Ketamine Nasal Spray” offered by www.medshopinc.com.\u003C\u002Fp>\u003Cp>FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.\u003C\u002Fp>\u003Cp>FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a \"black box warning,\" which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.\u003C\u002Fp>\u003Cp>\u003Cem>Misbranded Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&amp;C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering this drug for sale to U.S. consumers, www.medshopinc.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725157” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, PharmD\u003Cbr>Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Frisk-evaluation-and-mitigation-strategies-rems.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMed Shop Inc \u002F www.medshopinc.com\n\nNetherlands\n\ninfo@medshopinc.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 23, 2026\nWARNING LETTER\nReference Number: MARCS-CMS 725157\nTo Med Shop Inc:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.medshopinc.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, FDA has observed that www.medshopinc.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\nThere are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.\nAccordingly, FDA requests that www.medshopinc.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nFDA Review\nViolations were identified and documented during a review of your website www.medshopinc.com, FDA Establishment Identifier (FEI) 3043544193, on February 27, 2026.\nViolations of the Federal Food, Drug, and Cosmetic Act\nOn your website at internet address www.medshopinc.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 352(f)(1), 353(b)(1), and 355(a)).\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nCertain products offered for sale by www.medshopinc.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.\nYou failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.\nAn example of an unapproved ketamine drug product you offer for sale on www.medshopinc.com is esketamine marketed as \"Ketamine Nasal Spray.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Ketamine Nasal Spray is a powerful treatment option designed for individuals suffering from treatment-resistant depression and chronic pain. Administered as a nasal spray, it offers rapid relief by acting on NMDA receptors in the brain.\"\nWhile there are FDA-approved versions of ketamine drug products on the market in the United States, there is no approved drug application pursuant to section 505 of the FD&C Act in effect for \"Ketamine Nasal Spray” offered by www.medshopinc.com.\nFDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.\nFDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a \"black box warning,\" which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.\nMisbranded Drug Violations\nA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nYou failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.medshopinc.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725157” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, PharmD\nDirector\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_____________________\n1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Frisk-evaluation-and-mitigation-strategies-rems.","Med Shop Inc \u002F www.medshopinc.com","med-shop-inc-wwwmedshopinccom-725157-06232026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmed-shop-inc-wwwmedshopinccom-725157-06232026","2026-10-26T08:09:22.584147+00:00","2026-07-07","725157","2026-08-19T04:31:46.704+00:00","2026-06-23",{"id":142,"raw":143,"subject":37,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":42,"fei_number":20,"letter_url":149,"updated_at":150,"action_type":23,"case_status":24,"posted_date":45,"marcs_cms_no":151,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":152,"delivery_method":83,"recipient_title":20,"reference_number":20,"action_taken_date":48,"medical_device_id":20,"response_letter_date":20},637,[34,35,144,11,37,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-medical-spa-dba-cosmo-med-spa-715873-09092025\">Cosmo Medical Spa dba Cosmo Med Spa\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cosmo Medical Spa dba Cosmo Med Spa\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1068-8321 Kennedy Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Markham\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L3R5N4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@cosmomedspa.com\"> info@cosmomedspa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Cosmo Med Spa:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fcosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic (semaglutide) injection (4 weeks supply)”\u003C\u002Fli>\u003Cli>“Ozempic (semaglutide) injection (10 weeks supply)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D. Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nCosmo Medical Spa dba Cosmo Med Spa\n\n1068-8321 Kennedy Rd\n\nMarkham ON L3R5N4\n\nCanada\n\ninfo@cosmomedspa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nCosmo Med Spa:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fcosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.1 As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide products appear on your website:\n“Ozempic (semaglutide) injection (4 weeks supply)”\n“Ozempic (semaglutide) injection (10 weeks supply)”\nCompounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D. Director\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n______________________\n1 The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Cosmo Medical Spa dba Cosmo Med Spa","cosmo-medical-spa-dba-cosmo-med-spa-715873-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-medical-spa-dba-cosmo-med-spa-715873-09092025","2026-10-26T08:08:18.730704+00:00","715873","2026-08-19T16:19:52.144+00:00",{"id":154,"raw":155,"subject":130,"body_html":157,"body_text":158,"firm_name":159,"letter_id":160,"created_at":19,"fei_number":20,"letter_url":161,"updated_at":162,"action_type":23,"case_status":24,"posted_date":137,"marcs_cms_no":163,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":164,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":140,"medical_device_id":20,"response_letter_date":20},58,[126,127,156,11,130,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fketa-med-lab-wwwketamedlabcom-725154-06232026\">Keta Med Lab \u002F www.ketamedlab.com\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Keta Med Lab \u002F www.ketamedlab.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@ketamedlab.com\"> info@ketamedlab.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 23, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: MARCS-CMS 725154\u003C\u002Fp>\u003Cp>To Keta Med Lab:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketamedlab.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, FDA has observed that www.ketamedlab.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\u003C\u002Fp>\u003Cp>There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.\u003C\u002Fp>\u003Cp>Accordingly, FDA requests that www.ketamedlab.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website www.ketamedlab.com, FDA Establishment Identifier (FEI) 3043543982, on February 26, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On your website at internet address www.ketamedlab.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>Unapproved New Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.ketamedlab.com are drugs within the meaning of section 201(g) of the FD&amp;C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>You failed to obtain approved applications pursuant to section 505 of the FD&amp;C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved ketamine drug product you offer for sale on www.ketamedlab.com is ketamine marketed as \"Buy Ketamine Liquid Online.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Ketamine is most often used in veterinary medicine. In humans, it can induce and maintain general anesthesia before, during, and after surgery.\"\u003C\u002Fp>\u003Cp>A second example of an unapproved ketamine drug product you offer for sale on www.ketamedlab.com is ketamine marketed as \"Break Free from Depression with Ketamine Troches.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim \"Ketamine troches are gaining attention in mental health treatment. They offer a unique approach to managing depression.\"\u003C\u002Fp>\u003Cp>A third example of an unapproved ketamine drug product you offer for sale on www.ketamedlab.com is esketamine marketed as \"Buy ketamine Nasal Spray.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims \"Ketamine nasal spray is a treatment primarily used for individuals with treatment-resistant depression.\"\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of ketamine drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for \"Buy Ketamine Liquid Online,\" \"Break Free from Depression with Ketamine Troches,\" and \"Buy ketamine Nasal Spray\" offered by www.ketamedlab.com.\u003C\u002Fp>\u003Cp>FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.\u003C\u002Fp>\u003Cp>FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a \"black box warning,\" which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.\u003C\u002Fp>\u003Cp>\u003Cem>Misbranded Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>You failed to bear adequate directions for use on the labeling for these drug products that you have introduced into interstate commerce. Because the aforementioned drugs are prescription drugs intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&amp;C Act. Because these drugs are not approved in the United States, they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering these drugs for sale to U.S. consumers, www.ketamedlab.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug products without requiring a prescription, www.ketamedlab.com jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&amp;C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725154” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, PharmD\u003Cbr>Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Frisk-evaluation-and-mitigation-strategies-rems.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nKeta Med Lab \u002F www.ketamedlab.com\n\nUnited States\n\ninfo@ketamedlab.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 23, 2026\nWARNING LETTER\nReference Number: MARCS-CMS 725154\nTo Keta Med Lab:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketamedlab.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, FDA has observed that www.ketamedlab.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\nThere are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.\nAccordingly, FDA requests that www.ketamedlab.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nFDA Review\nViolations were identified and documented during a review of your website www.ketamedlab.com, FDA Establishment Identifier (FEI) 3043543982, on February 26, 2026.\nViolations of the Federal Food, Drug, and Cosmetic Act\nOn your website at internet address www.ketamedlab.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nCertain products offered for sale by www.ketamedlab.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.\nYou failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.\nAn example of an unapproved ketamine drug product you offer for sale on www.ketamedlab.com is ketamine marketed as \"Buy Ketamine Liquid Online.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Ketamine is most often used in veterinary medicine. In humans, it can induce and maintain general anesthesia before, during, and after surgery.\"\nA second example of an unapproved ketamine drug product you offer for sale on www.ketamedlab.com is ketamine marketed as \"Break Free from Depression with Ketamine Troches.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim \"Ketamine troches are gaining attention in mental health treatment. They offer a unique approach to managing depression.\"\nA third example of an unapproved ketamine drug product you offer for sale on www.ketamedlab.com is esketamine marketed as \"Buy ketamine Nasal Spray.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims \"Ketamine nasal spray is a treatment primarily used for individuals with treatment-resistant depression.\"\nWhile there are FDA-approved versions of ketamine drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for \"Buy Ketamine Liquid Online,\" \"Break Free from Depression with Ketamine Troches,\" and \"Buy ketamine Nasal Spray\" offered by www.ketamedlab.com.\nFDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.\nFDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a \"black box warning,\" which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.\nMisbranded Drug Violations\nA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nYou failed to bear adequate directions for use on the labeling for these drug products that you have introduced into interstate commerce. Because the aforementioned drugs are prescription drugs intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. Because these drugs are not approved in the United States, they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.ketamedlab.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.\nFurthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug products without requiring a prescription, www.ketamedlab.com jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725154” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, PharmD\nDirector\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n___________________________\n1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Frisk-evaluation-and-mitigation-strategies-rems.","Keta Med Lab \u002F www.ketamedlab.com","keta-med-lab-wwwketamedlabcom-725154-06232026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fketa-med-lab-wwwketamedlabcom-725154-06232026","2026-10-26T08:09:08.548436+00:00","725154","2026-08-19T04:31:06.052+00:00",{"id":166,"raw":167,"subject":56,"body_html":171,"body_text":172,"firm_name":173,"letter_id":174,"created_at":42,"fei_number":20,"letter_url":175,"updated_at":176,"action_type":23,"case_status":24,"posted_date":177,"marcs_cms_no":178,"product_type":66,"closeout_date":20,"issuing_office":55,"recipient_name":179,"body_fetched_at":180,"delivery_method":107,"recipient_title":20,"reference_number":20,"action_taken_date":181,"medical_device_id":20,"response_letter_date":20},519,[168,169,170,55,56,13,13,13],"\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-03T04:00:00Z\">10\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fqianjiang-kingphar-medical-material-co-ltd-716715-10032025\">Qianjiang Kingphar Medical Material Co Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wang Jun\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Qianjiang Kingphar Medical Material Co Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Yuanguang Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Qianjiang Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hubei Sheng\u003C\u002Fspan>, \u003Cspan>433100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Daniel@qjmdmgauze.com\"> Daniel@qjmdmgauze.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #716715\u003C\u002Fp>\u003Cp>October 3, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Wang Jun:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Qianjiang, China from June 30, 2025, through July 3, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures surgical masks, wound dressings, sterilization wraps, and surgical drapes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current Good Manufacturing Practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Wang Jun, General Manager, dated July 21, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality as required by 21 CFR 820.70(e).\u003C\u002Fp>\u003Cp>Specifically, your firm conducts manufacturing and packaging operations in ISO 8 cleanrooms and has failed to develop adequate cleaning and inspection procedures for floors, walls, and surfaces in their Packaging Clean Room (Sterile Barrier Sealing) and in their Woven Gauze Clean Room (Automated Cutting\u002FFolding) to prevent uncontrollable contamination. For example:\u003C\u002Fp>\u003Cp>a. The investigator observed structural issues in which floor molding is pulling away from the wall and ceiling molding deficiencies that do not allow for effective cleaning to prevent contamination of product(s).\u003C\u002Fp>\u003Cp>b. The investigator observed and documented dirt and filth accumulation on walls and floors in multiple areas with focal areas of concentrated filth especially under chairs, carts, machines, and any area where floor tape was used post cleaning.\u003C\u002Fp>\u003Cp>c. The investigator noted that your firm’s Weekly Quality Department Inspection Sheet and the Daily Log Sheet for Clean Room Disinfection are not accurate as these documents state that walls, floors, ceilings, and lighting fixtures were clean; however, the investigator observed dirt in multiple areas in the clean rooms.\u003C\u002Fp>\u003Cp>This is a repeat observation from your previous 2013 FDA inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. CDRH acknowledges that your firm’s response states your firm’s Quality manager revised and improved the \"Cleanliness Procedure for Clean Areas\" (Q\u002FY014-15), formulated the cleaning methods and frequency for tape stains, and organized all cleaning workers, quality inspectors, and workshop supervisors to conduct training on the revised documents. Additionally, your firm provided a training record that states that this training record is for ‘Cleanroom cleaning instruction’ and a revised inspection check list that includes tape residue removal. However, your firm did not submit the following:\u003C\u002Fp>\u003Cp>i. Revised \"Cleanliness Procedure for Clean Areas\" (Q\u002FY014-15);\u003C\u002Fp>\u003Cp>ii. Procedure for the training of \"Cleanliness Procedure for Clean Areas\" (Q\u002FY014-15);\u003C\u002Fp>\u003Cp>iii. Procedure for conducting environmental inspections to include identification of structural issues and corrective actions;\u003C\u002Fp>\u003Cp>iv. Procedure for the environmental inspection training; and,\u003C\u002Fp>\u003Cp>v. Retrospective review to identify whether the inadequate contamination controls have had an adverse impact on previously manufactured product(s).\u003C\u002Fp>\u003Cp>The Agency remains concerned with your firm’s ability to adequately identify potential environmental excursions within your controlled cleanroom environments or to mitigate subsequent product contamination events resulting from cleanroom contamination.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\u003C\u002Fp>\u003Cp>For example: Your firm has not developed alert\u002Fwarning limits for non-viable and viable (microbial) particle count levels based on historical performance data to demonstrate adequate environmental control of your ISO 8 clean rooms per ISO 14644-2, \u003Cem>Cleanrooms and associated controlled environments- Part 2: Monitoring to provide evidence of cleanroom performance related to air cleanliness by air particle concentration\u003C\u002Fem>, which was referenced in your Environment microbiological inspection instruction document. Additionally, your firm’s procedures were not clear regarding the handling of excursions of non-viable and viable particle count limits and gave the example that there were no “breach handling provisions” in the Environmental Controls Procedures or Microbiological Testing Procedures.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and concluded that the adequacy cannot be determined at this time. CDRH acknowledges that your firm’s response states that \"Environmental Microbial Testing and Control Work Instruction” (Q\u002FQY026-2) has been revised to include the alert\u002Fwarning level and action level standards for suspended particles based on historical data and training was conducted. However, you did not include a report that analyzes and determines these levels, and your firm did not conduct a retrospective review of data against these alert\u002Fwarning levels. Additionally, the revised procedure does not include your firm’s analysis, and it does not include investigation actions when an excursion occurs.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Stephen Anisko at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case #716715” when replying. If you have any questions about the contents of this letter, please contact: Claire Briglia at Claire.Briglia@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Raquel Peat, PhD, MPH, USPHS&nbsp;&nbsp;\u003Cbr>Acting Director\u003Cbr>OHT4: Office of Surgical and Infection Control Devices&nbsp;&nbsp;\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Richard Peppard\u003Cbr>2200 Lucerne Circle\u003Cbr>Green Bay, WI 54301\u003Cbr>Email: jdpeppard@sbcglobal.net\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nWang Jun\n\nRecipient Title\n\nGeneral Manager\n\nQianjiang Kingphar Medical Material Co Ltd.\n\nYuanguang Road\n\nQianjiang Shi\n\nHubei Sheng, 433100\n\nChina\n\nDaniel@qjmdmgauze.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #716715\nOctober 3, 2025\nDear Mr. Wang Jun:\nDuring an inspection of your firm located in Qianjiang, China from June 30, 2025, through July 3, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures surgical masks, wound dressings, sterilization wraps, and surgical drapes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current Good Manufacturing Practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Wang Jun, General Manager, dated July 21, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality as required by 21 CFR 820.70(e).\nSpecifically, your firm conducts manufacturing and packaging operations in ISO 8 cleanrooms and has failed to develop adequate cleaning and inspection procedures for floors, walls, and surfaces in their Packaging Clean Room (Sterile Barrier Sealing) and in their Woven Gauze Clean Room (Automated Cutting\u002FFolding) to prevent uncontrollable contamination. For example:\na. The investigator observed structural issues in which floor molding is pulling away from the wall and ceiling molding deficiencies that do not allow for effective cleaning to prevent contamination of product(s).\nb. The investigator observed and documented dirt and filth accumulation on walls and floors in multiple areas with focal areas of concentrated filth especially under chairs, carts, machines, and any area where floor tape was used post cleaning.\nc. The investigator noted that your firm’s Weekly Quality Department Inspection Sheet and the Daily Log Sheet for Clean Room Disinfection are not accurate as these documents state that walls, floors, ceilings, and lighting fixtures were clean; however, the investigator observed dirt in multiple areas in the clean rooms.\nThis is a repeat observation from your previous 2013 FDA inspection.\nWe reviewed your firm’s response and concluded that it is not adequate. CDRH acknowledges that your firm’s response states your firm’s Quality manager revised and improved the \"Cleanliness Procedure for Clean Areas\" (Q\u002FY014-15), formulated the cleaning methods and frequency for tape stains, and organized all cleaning workers, quality inspectors, and workshop supervisors to conduct training on the revised documents. Additionally, your firm provided a training record that states that this training record is for ‘Cleanroom cleaning instruction’ and a revised inspection check list that includes tape residue removal. However, your firm did not submit the following:\ni. Revised \"Cleanliness Procedure for Clean Areas\" (Q\u002FY014-15);\nii. Procedure for the training of \"Cleanliness Procedure for Clean Areas\" (Q\u002FY014-15);\niii. Procedure for conducting environmental inspections to include identification of structural issues and corrective actions;\niv. Procedure for the environmental inspection training; and,\nv. Retrospective review to identify whether the inadequate contamination controls have had an adverse impact on previously manufactured product(s).\nThe Agency remains concerned with your firm’s ability to adequately identify potential environmental excursions within your controlled cleanroom environments or to mitigate subsequent product contamination events resulting from cleanroom contamination.\n2. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\nFor example: Your firm has not developed alert\u002Fwarning limits for non-viable and viable (microbial) particle count levels based on historical performance data to demonstrate adequate environmental control of your ISO 8 clean rooms per ISO 14644-2, Cleanrooms and associated controlled environments- Part 2: Monitoring to provide evidence of cleanroom performance related to air cleanliness by air particle concentration, which was referenced in your Environment microbiological inspection instruction document. Additionally, your firm’s procedures were not clear regarding the handling of excursions of non-viable and viable particle count limits and gave the example that there were no “breach handling provisions” in the Environmental Controls Procedures or Microbiological Testing Procedures.\nWe reviewed your firm's response and concluded that the adequacy cannot be determined at this time. CDRH acknowledges that your firm’s response states that \"Environmental Microbial Testing and Control Work Instruction” (Q\u002FQY026-2) has been revised to include the alert\u002Fwarning level and action level standards for suspended particles based on historical data and training was conducted. However, you did not include a report that analyzes and determines these levels, and your firm did not conduct a retrospective review of data against these alert\u002Fwarning levels. Additionally, the revised procedure does not include your firm’s analysis, and it does not include investigation actions when an excursion occurs.\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Stephen Anisko at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case #716715” when replying. If you have any questions about the contents of this letter, please contact: Claire Briglia at Claire.Briglia@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nRDML Raquel Peat, PhD, MPH, USPHS\nActing Director\nOHT4: Office of Surgical and Infection Control Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nRichard Peppard\n2200 Lucerne Circle\nGreen Bay, WI 54301\nEmail: jdpeppard@sbcglobal.net","Qianjiang Kingphar Medical Material Co Ltd.","qianjiang-kingphar-medical-material-co-ltd-716715-10032025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fqianjiang-kingphar-medical-material-co-ltd-716715-10032025","2026-10-26T08:09:46.045817+00:00","2025-10-28","716715","Wang Jun","2026-08-19T16:12:28.68+00:00","2025-10-03",{"id":183,"raw":184,"subject":189,"body_html":190,"body_text":191,"firm_name":192,"letter_id":193,"created_at":194,"fei_number":20,"letter_url":195,"updated_at":196,"action_type":23,"case_status":24,"posted_date":197,"marcs_cms_no":198,"product_type":199,"closeout_date":20,"issuing_office":188,"recipient_name":200,"body_fetched_at":201,"delivery_method":202,"recipient_title":20,"reference_number":20,"action_taken_date":203,"medical_device_id":20,"response_letter_date":20},1485,[185,186,187,188,189,13,13,13],"\u003Ctime datetime=\"2024-05-07T04:00:00Z\">05\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-01T04:00:00Z\">05\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmariscos-perla-mar-s-de-rl-682814-05012024\">Mariscos Perla Mar S. de R.L.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Kiara Trejo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mariscos Perla Mar S. de R.L.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Carretera al Muelle de Cabotaje\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>La Ceiba\u003C\u002Fspan>, \u003Cspan>Atlántida\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Honduras\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Northoceanica.hn@gmail.com\"> Northoceanica.hn@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 1, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Reference CMS #682814\u003C\u002Fp>\u003Cp>Dear Ms. Kiara Trejo:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted a Foreign Regulatory Assessment (FRRA) of your seafood processing facility, Mariscos Perla Mar S. de R.L., located at Carretera al Muelle de Cabotaje, La Ceiba, Atlántida, Honduras, on January 22 - 26, 2024. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). That inspection resulted in FDA’s issuance of an FDA-483, Inspectional Observations, listing the deviations found at your firm at the conclusion of the inspection. We acknowledge receipt of your response via email on February 14, 2024. Your response included a revised HACCP plans for frozen raw lobster meat bags and frozen raw conch fillets dated January 2024 and other HACCP related documents. However, our evaluation of your response revealed it was not adequate as further described in this letter.\u003C\u002Fp>\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen raw lobster head meat and frozen raw conch fillets products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\u003Cp>1. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur to comply with 21 CFR 123.6(a) and (c)(1). A “food safety hazard” is defined in 21 CFR 123.3(f) as a “any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.” However, your HACCP plans for frozen raw lobster head meat and frozen raw conch fillets that are thawed in reduced oxygen packaging (i.e., ROP) do not identify \u003Cem>Clostridium botulinum \u003C\u002Fem>growth and toxin formation as a food safety hazard at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step. Your firm thaws the frozen raw lobster meat bags and frozen raw conch in closed plastic bags at temperatures between \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F - \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F for \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours or longer until the internal temperature of the product reaches \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F - \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F. The conch and lobster units in the bags are unlikely to thaw at a uniform rate which can allow for deterioration of units that thaw more quickly and continue to be exposed to the described temperatures and allowing for potential \u003Cem>C. botulinum\u003C\u002Fem> growth and toxin formation. The times and temperatures for thawing are potentially unsafe and can also allow for a portion of the products to become adulterated due to decomposition or deterioration.\u003C\u002Fp>\u003Cp>For additional guidance and control strategies, you may reference the Fish and Fishery –––––Products Hazards &amp; Controls Guidance - June 2022 4th Edition at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload, Chapter 13 for Clostridium botulinum Toxin Formation and Table A-4 Appendix 4 Bacterial Pathogen Growth and Inactivation.\u003C\u002Fp>\u003Cp>2. You must maintain adequate sanitation control records that, at a minimum, document monitoring and corrections set out in 21 CFR 123.11(b), to comply with 21 CFR 123.11(c). Specifically, the daily sanitation monitoring records obtained by our investigator do not provide coverage of prevention of cross-contamination from insanitary objects, protection of food and packaging material from adulteration, proper labeling, storage, and use of toxic compounds, and control of employee health conditions. We acknowledge receipt of your corrected sanitation monitoring record showing that you are now monitoring your conditions and controls for the exclusion of pests. However, your records and procedures should also be corrected to address the other sanitation conditions and controls.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your HACCP plans for frozen raw lobster head meat and frozen raw conch fillets, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products with English translations) to demonstrate implementation of the plans, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert 16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Giselle Jordan, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Giselle Jordan via email at: giselle.jordan@fda.hhs.gov. Please include reference #682814 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery and Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Kiara Trejo\n\nRecipient Title\n\nGeneral Manager\n\nMariscos Perla Mar S. de R.L.\n\nCarretera al Muelle de Cabotaje\n\nLa Ceiba, Atlántida\n\nHonduras\n\nNorthoceanica.hn@gmail.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nMay 1, 2024\nWARNING LETTER\nReference CMS #682814\nDear Ms. Kiara Trejo:\nThe United States Food and Drug Administration (FDA) conducted a Foreign Regulatory Assessment (FRRA) of your seafood processing facility, Mariscos Perla Mar S. de R.L., located at Carretera al Muelle de Cabotaje, La Ceiba, Atlántida, Honduras, on January 22 - 26, 2024. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). That inspection resulted in FDA’s issuance of an FDA-483, Inspectional Observations, listing the deviations found at your firm at the conclusion of the inspection. We acknowledge receipt of your response via email on February 14, 2024. Your response included a revised HACCP plans for frozen raw lobster meat bags and frozen raw conch fillets dated January 2024 and other HACCP related documents. However, our evaluation of your response revealed it was not adequate as further described in this letter.\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen raw lobster head meat and frozen raw conch fillets products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards & Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nYour significant deviations are as follows:\n1. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur to comply with 21 CFR 123.6(a) and (c)(1). A “food safety hazard” is defined in 21 CFR 123.3(f) as a “any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.” However, your HACCP plans for frozen raw lobster head meat and frozen raw conch fillets that are thawed in reduced oxygen packaging (i.e., ROP) do not identify Clostridium botulinum growth and toxin formation as a food safety hazard at the (b)(4) step. Your firm thaws the frozen raw lobster meat bags and frozen raw conch in closed plastic bags at temperatures between (b)(4)°F - (b)(4)°F for (b)(4) hours or longer until the internal temperature of the product reaches (b)(4)°F - (b)(4)°F. The conch and lobster units in the bags are unlikely to thaw at a uniform rate which can allow for deterioration of units that thaw more quickly and continue to be exposed to the described temperatures and allowing for potential C. botulinum growth and toxin formation. The times and temperatures for thawing are potentially unsafe and can also allow for a portion of the products to become adulterated due to decomposition or deterioration.\nFor additional guidance and control strategies, you may reference the Fish and Fishery –––––Products Hazards & Controls Guidance - June 2022 4th Edition at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload, Chapter 13 for Clostridium botulinum Toxin Formation and Table A-4 Appendix 4 Bacterial Pathogen Growth and Inactivation.\n2. You must maintain adequate sanitation control records that, at a minimum, document monitoring and corrections set out in 21 CFR 123.11(b), to comply with 21 CFR 123.11(c). Specifically, the daily sanitation monitoring records obtained by our investigator do not provide coverage of prevention of cross-contamination from insanitary objects, protection of food and packaging material from adulteration, proper labeling, storage, and use of toxic compounds, and control of employee health conditions. We acknowledge receipt of your corrected sanitation monitoring record showing that you are now monitoring your conditions and controls for the exclusion of pests. However, your records and procedures should also be corrected to address the other sanitation conditions and controls.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your HACCP plans for frozen raw lobster head meat and frozen raw conch fillets, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products with English translations) to demonstrate implementation of the plans, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert 16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nPlease send your reply to the Food and Drug Administration, Attention: Giselle Jordan, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Giselle Jordan via email at: giselle.jordan@fda.hhs.gov. Please include reference #682814 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nAnn M. Oxenham, J.D.\nDirector\nOffice of Compliance\nCenter for Food Safety and Applied Nutrition","Mariscos Perla Mar S. de R.L.","mariscos-perla-mar-s-de-rl-682814-05012024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmariscos-perla-mar-s-de-rl-682814-05012024","2026-10-26T08:09:20.673408+00:00","2024-05-07","682814","Food & Beverages","Ms. Kiara Trejo","2026-08-20T00:07:30.652+00:00","Via Express Delivery and Electronic Mail","2024-05-01",{"id":205,"raw":206,"subject":210,"body_html":211,"body_text":212,"firm_name":213,"letter_id":214,"created_at":215,"fei_number":20,"letter_url":216,"updated_at":217,"action_type":23,"case_status":24,"posted_date":218,"marcs_cms_no":219,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":220,"body_fetched_at":221,"delivery_method":222,"recipient_title":20,"reference_number":223,"action_taken_date":224,"medical_device_id":20,"response_letter_date":20},22011,[207,208,209,11,210,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-22T04:00:00Z\">10\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-nuclear-medicine-llc-736893-10222026\">Northland Nuclear Medicine, LLC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                          \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-08\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nathan J. Fleck, Pharm.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Northland Nuclear Medicine, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1815 Michigan Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bismarck\u003C\u002Fspan>, \u003Cspan>ND\u003C\u002Fspan> \u003Cspan>58504-6121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-08\u003C\u002Fp>\u003Cp>To Dr. Nathan J. Fleck:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Northland Nuclear Medicine, LLC, FDA Establishment Identifier (FEI) 3005334016, located at 1815 Michigan Ave., Bismarck, from May 26 to 29, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your June 11, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations observed during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications (21 CFR 212.20(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Investigation of Out-of-Limit Environmental Monitoring Results\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to adequately investigate out-of-limit (OOL) environmental monitoring (EM) results, identify the root cause of recurring microbial recoveries, and implement appropriate corrective actions. EM data from March 2024 through April 2026 revealed an adverse trend with over 100 microbial recoveries from ISO 5 areas (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> and laminar airflow workstation (LAFW)), including counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs). These recoveries were not formally identified, preventing your firm from conducting adequate investigations. More than 90 ISO 5 isolates were documented as “resembles previously identified \u003Cem>Bacillus\u003C\u002Fem> colonies” or “resembles previously identified colonies” in lieu of formal microbial identification, with no record of which previously identified organism the colony purportedly resembled. Since December 2024, of approximately 75 ISO 5 microbial recoveries, only two were sent for formal identification. No genus or species recovered in ISO 5 areas has been recorded in your EM log since September 2025. Operator training for interpreting \u003Cstrong>(b)(4)\u003C\u002Fstrong> plate results consisted of a single presentation slide instructing personnel to “count CFUs and record results,” with no instruction regarding microbial identification.\u003C\u002Fp>\u003Cp>Additionally, \u003Cstrong>(b)(4)\u003C\u002Fstrong> ISO 7 cleanroom certification results for areas surrounding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and LAFW revealed microbial recoveries that exceeded your action limits and were not adequately investigated. For example, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU active air recovery described as bacterial and yeast was not adequately identified because the sample plates were received with \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the lid. For a \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU recovery sent for identification, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were identified as \u003Cem>Pseudopithomyces palmicola\u003C\u002Fem> and the remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were identified as \u003Cem>Micrococcus\u003C\u002Fem> spp. and coryneform bacillus. Investigations were not initiated. Further, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product review acknowledges “excess CFUs as an ongoing issue in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom.”\u003C\u002Fp>\u003Cp>Your firm systematically failed to adequately investigate out-of-limit environmental monitoring results, to identify root causes of recurring microbial contamination in critical ISO 5 areas, and to implement effective corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>In your response, you commit to ensuring that future microbial colony recoveries from ISO 5 areas will be properly identified and documented. Your response is inadequate because it does not include a retrospective assessment of the unidentified recoveries or an evaluation of adverse trends, does not assess the adequacy of past batch release decisions made in the absence of organism identification, and does not address the documented presence of spore-forming bacteria and fungi in your ISO-classified environments.\u003C\u002Fp>\u003Cp>Environmental isolate identification data provides essential information for an investigation into routes of contamination, such as when investigating an adverse environmental control trend, media fill contamination, or a product sterility testing failure. EM should include routine identification of microorganisms to the species (or, where appropriate, genus) level, including isolates recovered from an ISO 5 environment, its surrounding cleanroom, and personnel.\u003C\u002Fp>\u003Cp>It is essential that cleaning and disinfection procedures are described in sufficient detail, including the preparation, disinfectant selection, and contact time to enable reproducibility and ensure that potential contaminants are adequately removed from surfaces. The effectiveness of disinfection procedures should be evaluated through a routine EM program, and adverse trends should prompt reassessment of disinfectant selection, concentration, contact time, and application frequency.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Investigation and CAPA for Recurring Manufacturing Deficiencies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to conduct adequate effectiveness checks for CAPAs to prevent recurrence.\u003C\u002Fp>\u003Cp>Multiple CAPAs for recurring low \u003Cstrong>(b)(4)\u003C\u002Fstrong> yields were closed without your required effectiveness checks. Yields continued to fall below your established \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit. No investigations were initiated for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches manufactured between August 2024 and April 2025 that failed the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit, with yields as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Rather than identifying and correcting the root cause, you lowered the yield limit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Yields subsequently fell below your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit. Notably, Incident Report NNM 2025 08 states, “This has been an ongoing issue now for more than a year. We are continuing to evaluate the situation in an attempt to increase yields.” The effectiveness check for that incident was marked “No” with no additional corrective action identified. You continue to manufacture your PET drug without resolving the root cause of the low yields.\u003C\u002Fp>\u003Cp>PET drug producers must establish appropriate action limits for radiochemical yield and investigate and correct the root cause when those limits are exceeded. Low yields or a downward trend in yield are recognized indicators that the production process may be losing control. Lowering a yield limit to accommodate a failing process does not satisfy this requirement. Producers must maintain adequate production and process controls to ensure consistent production and must implement appropriate CAPA to prevent recurrence of nonconforming results.\u003C\u002Fp>\u003Cp>In your response, you commit to retrain manufacturing personnel on effectiveness check requirements and to formally complete the incident report form. Your response is inadequate because you have not conducted a retrospective evaluation of the batches manufactured and it fails to address the root cause of the persistent low-yield problem. Additionally, your response does not address the adequacy of lowering your yield limit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% as a corrective measure in lieu of identifying and resolving the root cause of persistent yield failures.\u003C\u002Fp>\u003Cp>To ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Training alone does not address the systemic failures that allowed deficient investigations to persist undetected by quality unit (QU) oversight.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\u003Cbr>o establishing appropriate limits,\u003Cbr>o sampling methods,\u003Cbr>o sampling locations and frequencies,\u003Cbr>o trend analysis,\u003Cbr>o appropriate investigation of deviations and adverse trends,\u003Cbr>o and a comprehensive CAPA plan based on the findings of the assessment.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\u003Cbr>o staff competencies (including use of appropriate subject matter experts)\u003Cbr>o written procedures\u003Cbr>o scientific rigor and foundation\u003Cbr>o scope determination\u003Cbr>o root cause evaluations\u003Cbr>o CAPA effectiveness\u003Cbr>o quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted.\u003Cbr>o and, based on above, detailed systemic improvements to the investigation system\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o a determination of whether procedures used by your firm are robust and\u003Cbr>o appropriate\u003Cbr>o provisions for QU oversight throughout your operations to evaluate\u003Cbr>o adherence to appropriate practices\u003Cbr>o a complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Control of Environmental Monitoring Plates\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately control your EM contact plates used to monitor your production operations.\u003C\u002Fp>\u003Cp>EM plates were stored inside a \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing a significant amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution before and after sampling. You failed to assess the impact of this practice on microbial recovery.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is a \u003Cstrong>(b)(4)\u003C\u002Fstrong> with well-documented sporicidal activity. Exposure of EM plates to \u003Cstrong>(b)(4)\u003C\u002Fstrong> can kill or suppress the microorganisms these tests are designed to recover, rendering results unreliable and potentially generating false negatives.\u003C\u002Fp>\u003Cp>In your response, you state that personnel have stopped spraying EM plates and that procedures have been updated accordingly. Your response is inadequate because it does not address the reliability of historical EM data collected using the compromised methodology, does not include a retrospective assessment of past EM results that were affected by \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure, and does not evaluate the adequacy of prior batch release decisions made in the absence of reliable environmental monitoring data.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Airflow Visualization Studies (Smoke Studies)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to ensure adequate control of airflow in the ISO 5 critical aseptic processing area. Smoke studies conducted at your facility did not include a dynamic evaluation of LAFW or \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations and therefore do not adequately demonstrate that unidirectional airflow effectively controls air quality during aseptic manufacturing.\u003C\u002Fp>\u003Cp>Adequate contamination control in an aseptic PET drug manufacturing environment requires that monitoring tools, disinfection practices, and airflow qualification studies be designed and executed in a manner that meaningfully protects the sterility of the product. Compromised environmental monitoring media, inadequate airflow qualification, and failure to disinfect product-contact surfaces prior to aseptic operations collectively undermine the sterility assurance of your PET drugs.\u003C\u002Fp>\u003Cp>In your response, you commit to include transfer of starting components and materials prior to mock operations going forward. Your response is inadequate because you do not address the absence of a validated, dynamic evaluation of actual LAFW and \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations under representative conditions.\u003C\u002Fp>\u003Cp>\u003Cem>Failure to Adequately Disinfect \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately disinfect the exterior surfaces of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to aseptic manufacturing operations and failed to establish written procedures for the cleaning and disinfection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces.\u003C\u002Fp>\u003Cp>In your response, you indicate that personnel were informed and retrained on the procedures for proper disinfection. Your response is inadequate because it does not establish a written disinfection procedure for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a required step in your aseptic manufacturing process.\u003C\u002Fp>\u003Cp>PET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients. Cleaning and disinfection should be performed frequently to ensure consistent control of environmental quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\u003Cbr>o unique labeling of each sample\u003Cbr>o signatures of all staff who handle the sample\u003Cbr>o complete tracking of sample integrity and custody\u003Cbr>o date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\u003Cbr>o digital time-stamped photos of all plates\u003Cbr>o signatures of personnel performing reading of microbial counts\u003Cbr>o provisions for verifications and routine quality assurance oversight.\u003C\u002Fli>\u003Cli>Comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o all human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o facility layout\u003Cbr>o personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\u003Cbr>o disinfection practices and procedures\u003Cbr>o specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A thorough, independent evaluation of airflow unidirectionality in your aseptic process. Ensure smoke studies are conducted under dynamic conditions, with comprehensive evaluations of aseptic processing airflow unidirectionality, including the impact of aseptic interventions and surrounding cleanroom hazards. Conduct the smoke studies after you remediate your aseptic operation, using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a regulatory meeting held on December 13, 2023, FDA discussed similar CGMP violations. You proposed specific remediation for these violations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Guidance on PET Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>PET Drugs—Current Good Manufacturing Practice\u003C\u002Fem>, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3005334016 and ATTN: Compliance officer Michael Klapal in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-08\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nNathan J. Fleck, Pharm.D.\n\nRecipient Title\n\nPresident & Owner\n\nNorthland Nuclear Medicine, LLC\n\n1815 Michigan Ave.\n\nBismarck, ND 58504-6121\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 22, 2026\nWARNING LETTER\nReference number: 320-27-08\nTo Dr. Nathan J. Fleck:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Northland Nuclear Medicine, LLC, FDA Establishment Identifier (FEI) 3005334016, located at 1815 Michigan Ave., Bismarck, from May 26 to 29, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\nBecause your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your June 11, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations observed during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications (21 CFR 212.20(d)).\nInadequate Investigation of Out-of-Limit Environmental Monitoring Results\nYour firm failed to adequately investigate out-of-limit (OOL) environmental monitoring (EM) results, identify the root cause of recurring microbial recoveries, and implement appropriate corrective actions. EM data from March 2024 through April 2026 revealed an adverse trend with over 100 microbial recoveries from ISO 5 areas (e.g., (b)(4) and laminar airflow workstation (LAFW)), including counts of (b)(4) colony forming units (CFUs). These recoveries were not formally identified, preventing your firm from conducting adequate investigations. More than 90 ISO 5 isolates were documented as “resembles previously identified Bacillus colonies” or “resembles previously identified colonies” in lieu of formal microbial identification, with no record of which previously identified organism the colony purportedly resembled. Since December 2024, of approximately 75 ISO 5 microbial recoveries, only two were sent for formal identification. No genus or species recovered in ISO 5 areas has been recorded in your EM log since September 2025. Operator training for interpreting (b)(4) plate results consisted of a single presentation slide instructing personnel to “count CFUs and record results,” with no instruction regarding microbial identification.\nAdditionally, (b)(4) ISO 7 cleanroom certification results for areas surrounding your (b)(4) and LAFW revealed microbial recoveries that exceeded your action limits and were not adequately investigated. For example, a (b)(4) CFU active air recovery described as bacterial and yeast was not adequately identified because the sample plates were received with (b)(4) on the lid. For a (b)(4) CFU recovery sent for identification, (b)(4) CFU were identified as Pseudopithomyces palmicola and the remaining (b)(4) CFU were identified as Micrococcus spp. and coryneform bacillus. Investigations were not initiated. Further, your (b)(4) product review acknowledges “excess CFUs as an ongoing issue in the (b)(4) cleanroom.”\nYour firm systematically failed to adequately investigate out-of-limit environmental monitoring results, to identify root causes of recurring microbial contamination in critical ISO 5 areas, and to implement effective corrective action and preventive action (CAPA).\nIn your response, you commit to ensuring that future microbial colony recoveries from ISO 5 areas will be properly identified and documented. Your response is inadequate because it does not include a retrospective assessment of the unidentified recoveries or an evaluation of adverse trends, does not assess the adequacy of past batch release decisions made in the absence of organism identification, and does not address the documented presence of spore-forming bacteria and fungi in your ISO-classified environments.\nEnvironmental isolate identification data provides essential information for an investigation into routes of contamination, such as when investigating an adverse environmental control trend, media fill contamination, or a product sterility testing failure. EM should include routine identification of microorganisms to the species (or, where appropriate, genus) level, including isolates recovered from an ISO 5 environment, its surrounding cleanroom, and personnel.\nIt is essential that cleaning and disinfection procedures are described in sufficient detail, including the preparation, disinfectant selection, and contact time to enable reproducibility and ensure that potential contaminants are adequately removed from surfaces. The effectiveness of disinfection procedures should be evaluated through a routine EM program, and adverse trends should prompt reassessment of disinfectant selection, concentration, contact time, and application frequency.\nInadequate Investigation and CAPA for Recurring Manufacturing Deficiencies\nYou failed to conduct adequate effectiveness checks for CAPAs to prevent recurrence.\nMultiple CAPAs for recurring low (b)(4) yields were closed without your required effectiveness checks. Yields continued to fall below your established (b)(4)% limit. No investigations were initiated for approximately (b)(4) batches manufactured between August 2024 and April 2025 that failed the (b)(4)% limit, with yields as low as (b)(4)%. Rather than identifying and correcting the root cause, you lowered the yield limit from (b)(4)% to (b)(4)%. Yields subsequently fell below your revised (b)(4)% limit. Notably, Incident Report NNM 2025 08 states, “This has been an ongoing issue now for more than a year. We are continuing to evaluate the situation in an attempt to increase yields.” The effectiveness check for that incident was marked “No” with no additional corrective action identified. You continue to manufacture your PET drug without resolving the root cause of the low yields.\nPET drug producers must establish appropriate action limits for radiochemical yield and investigate and correct the root cause when those limits are exceeded. Low yields or a downward trend in yield are recognized indicators that the production process may be losing control. Lowering a yield limit to accommodate a failing process does not satisfy this requirement. Producers must maintain adequate production and process controls to ensure consistent production and must implement appropriate CAPA to prevent recurrence of nonconforming results.\nIn your response, you commit to retrain manufacturing personnel on effectiveness check requirements and to formally complete the incident report form. Your response is inadequate because you have not conducted a retrospective evaluation of the batches manufactured and it fails to address the root cause of the persistent low-yield problem. Additionally, your response does not address the adequacy of lowering your yield limit from (b)(4)% to (b)(4)% as a corrective measure in lieu of identifying and resolving the root cause of persistent yield failures.\nTo ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Training alone does not address the systemic failures that allowed deficient investigations to persist undetected by quality unit (QU) oversight.\nIn response to this letter, provide:\nAn independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\no establishing appropriate limits,\no sampling methods,\no sampling locations and frequencies,\no trend analysis,\no appropriate investigation of deviations and adverse trends,\no and a comprehensive CAPA plan based on the findings of the assessment.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\no staff competencies (including use of appropriate subject matter experts)\no written procedures\no scientific rigor and foundation\no scope determination\no root cause evaluations\no CAPA effectiveness\no quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted.\no and, based on above, detailed systemic improvements to the investigation system\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no a determination of whether procedures used by your firm are robust and\no appropriate\no provisions for QU oversight throughout your operations to evaluate\no adherence to appropriate practices\no a complete and final review of each batch and its related information before the QU disposition decision\no oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n2. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(b)).\nInadequate Control of Environmental Monitoring Plates\nYou failed to adequately control your EM contact plates used to monitor your production operations.\nEM plates were stored inside a (b)(4) containing a significant amount of (b)(4) solution before and after sampling. You failed to assess the impact of this practice on microbial recovery.\n(b)(4) is a (b)(4) with well-documented sporicidal activity. Exposure of EM plates to (b)(4) can kill or suppress the microorganisms these tests are designed to recover, rendering results unreliable and potentially generating false negatives.\nIn your response, you state that personnel have stopped spraying EM plates and that procedures have been updated accordingly. Your response is inadequate because it does not address the reliability of historical EM data collected using the compromised methodology, does not include a retrospective assessment of past EM results that were affected by (b)(4) exposure, and does not evaluate the adequacy of prior batch release decisions made in the absence of reliable environmental monitoring data.\nInadequate Airflow Visualization Studies (Smoke Studies)\nYour firm failed to ensure adequate control of airflow in the ISO 5 critical aseptic processing area. Smoke studies conducted at your facility did not include a dynamic evaluation of LAFW or (b)(4) operations and therefore do not adequately demonstrate that unidirectional airflow effectively controls air quality during aseptic manufacturing.\nAdequate contamination control in an aseptic PET drug manufacturing environment requires that monitoring tools, disinfection practices, and airflow qualification studies be designed and executed in a manner that meaningfully protects the sterility of the product. Compromised environmental monitoring media, inadequate airflow qualification, and failure to disinfect product-contact surfaces prior to aseptic operations collectively undermine the sterility assurance of your PET drugs.\nIn your response, you commit to include transfer of starting components and materials prior to mock operations going forward. Your response is inadequate because you do not address the absence of a validated, dynamic evaluation of actual LAFW and (b)(4) operations under representative conditions.\nFailure to Adequately Disinfect (b)(4)\nYou failed to adequately disinfect the exterior surfaces of the (b)(4) prior to aseptic manufacturing operations and failed to establish written procedures for the cleaning and disinfection of (b)(4) surfaces.\nIn your response, you indicate that personnel were informed and retrained on the procedures for proper disinfection. Your response is inadequate because it does not establish a written disinfection procedure for the (b)(4) as a required step in your aseptic manufacturing process.\nPET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients. Cleaning and disinfection should be performed frequently to ensure consistent control of environmental quality.\nIn response to this letter, provide:\nA comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\no unique labeling of each sample\no signatures of all staff who handle the sample\no complete tracking of sample integrity and custody\no date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\no digital time-stamped photos of all plates\no signatures of personnel performing reading of microbial counts\no provisions for verifications and routine quality assurance oversight.\nComprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no all human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\no equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no facility layout\no personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\no disinfection practices and procedures\no specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA thorough, independent evaluation of airflow unidirectionality in your aseptic process. Ensure smoke studies are conducted under dynamic conditions, with comprehensive evaluations of aseptic processing airflow unidirectionality, including the impact of aseptic interventions and surrounding cleanroom hazards. Conduct the smoke studies after you remediate your aseptic operation, using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nRepeat Violations at Facility\nIn a regulatory meeting held on December 13, 2023, FDA discussed similar CGMP violations. You proposed specific remediation for these violations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nGuidance on PET Drugs\nSee FDA’s guidance document, PET Drugs—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3005334016 and ATTN: Compliance officer Michael Klapal in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","Northland Nuclear Medicine, LLC","northland-nuclear-medicine-llc-736893-10222026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-nuclear-medicine-llc-736893-10222026","2026-11-17T01:02:03.701861+00:00","2026-10-27","736893","Nathan J. Fleck, Pharm.D.","2026-11-03T01:02:46.643+00:00","VIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-08","2026-10-22",{"id":226,"raw":227,"subject":231,"body_html":233,"body_text":234,"firm_name":235,"letter_id":236,"created_at":98,"fei_number":20,"letter_url":237,"updated_at":238,"action_type":23,"case_status":101,"posted_date":239,"marcs_cms_no":240,"product_type":66,"closeout_date":241,"issuing_office":55,"recipient_name":242,"body_fetched_at":243,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":244,"medical_device_id":20,"response_letter_date":20},2828,[228,229,230,55,231,13,232,13],"\u003Ctime datetime=\"2022-03-08T14:20:00Z\">03\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-07T05:00:00Z\">01\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwickimed-medical-equipment-manufacturing-co-ltd-623042-01072022\">Wickimed Medical Equipment Manufacturing Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwickimed-medical-equipment-manufacturing-co-ltd-623042-05232022\">\u003Ctime datetime=\"2022-06-02T04:00:00Z\">06\u002F02\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mac Lai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Wickimed Medical Equipment Manufacturing Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>XingWang Street, LiLin Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>ZhongKai Hi-Tech Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huizhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>516003\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 7, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Lai:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in HuiZhou China, on September 6, 2021 through September 14, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Class II Sterile Single Use Disposable Electrodes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received two response from you dated October 3, 2021 and October 20, 2021 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>Your firm’s responses dated November 24, 2021 and December 20, 2021 to the Form FDA 483 (FDA 483) was not reviewed because it was not received within fifteen business days of issuance of the FDA 483. The response will be evaluated along with any other written material provided in response to the violations cited in this Warning Letter. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm’s Control Procedures for Customer Feedback, Complaints and Return, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, has no requirement to ensure your firm is receiving complaints from its distributor that is marketing and selling the private label manufactured medical devices in the US market. Additionally, your firm has no documented agreement with its US private label distributor requiring them to provide your firm with complaints. It is important that your firm reviews and evaluates all complaints in a uniform and timely manner to determine whether an investigation is necessary and that they are evaluated to determine whether the complaint represents an event that is reportable under 21 CFR Part 806, Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm provided their revised Customer Feedback, Complaints, and Returns procedure, which your firm indicates establishes responsibility for complaint handling activities. Your response stated that this included the firm’s need to evaluate complaints to determine if an investigation is necessary and should be reported to the US FDA, for all new and existing customers. Your firm’s response stated it conducted the following actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Reviewed the FDA MAUDE database for the past 5 years and initiated customer complaints for the 3 MDRs found in order to perform complaint investigations.\u003C\u002Fli>\n\t\u003Cli>Revised its Contract Review Procedures.\u003C\u002Fli>\n\t\u003Cli>Provided training to the related personnel on both revised procedures. Retrospectively reviewed the EUDAMED and NMPA databases and found no complaints relating to your devices.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA. Additionally, your response does not reveal if the distributor has been contacted to determine if any complaints have been received.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm began sterilization activities for their private label sterile medical devices and contract manufactured medical devices on December 23, 2019. During the inspection, your firm was not able to provide detailed information on the sterilization validation process, nor objective evidence and data.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm acknowledges that it did not retain the raw data to support the report as there was no requirement for handwriting the data in its procedures. Your firm’s response stated that it conducted the following actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Reviewed its data for sterilization cycle records and were able to determine that there were no Biological Indicator failures for the past 3 years.\u003C\u002Fli>\n\t\u003Cli>Reviewed its customer complaints for the past three years to determine whether there were any complaints related to inadequate sterilization process or the sterility of their product.\u003C\u002Fli>\n\t\u003Cli>Conducted IQ\u002FOQ revalidation for the sterilization chamber that did not have handwritten data.\u003C\u002Fli>\n\t\u003Cli>Provided its draft Product Registration and Marketing Authorization control procedure.\u003C\u002Fli>\n\t\u003Cli>Provided its Revised Sterilization Process Control procedures.\u003C\u002Fli>\n\t\u003Cli>Conducted training on its new procedures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the responses for adequacy. Your firm should provide a complete English translated version of its documents to the FDA.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not adequately established Design Control procedures related to its line of private label manufactured Sterile Single Use Disposable Electrodes that are exported and intended for the US market. Your firm stated that it was not familiar with or could not provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Its design and development procedures.\u003C\u002Fli>\n\t\u003Cli>Explain what design and developments activities were conducted and the results.\u003C\u002Fli>\n\t\u003Cli>Provide nor locate all the documentation related to the Class II Sterile Single Use Disposable Electrodes (GEI), DHF and 510(k).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm conducted the following actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provided its revised Design and Development Management Procedure and trained its related personnel on the revised procedures.\u003C\u002Fli>\n\t\u003Cli>Conducted reverification and revalidation on the microneedles.\u003C\u002Fli>\n\t\u003Cli>Conducted a retrospective review of its DHF and found some missing objective data and evidence for its Electrosurgical Pencil with Electrode WP 200 Series.\u003C\u002Fli>\n\t\u003Cli>Conducted reverification and revalidation on the Electrosurgical Pencil with Electrode WP 200 series.\u003C\u002Fli>\n\t\u003Cli>Reviewed your design verification and validation for your other products and determined that the design verification and design validation reports had included objective data and evidence.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the responses for adequacy. Your firm should provide a complete English translated version of its documents to the FDA.\u003C\u002Fp>\n\n\u003Cp>4. Failure to identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86.\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not established procedures to properly identify medical devices labeled as \"Sterile\", which have not undergone the sterilization process are properly and conspicuously identified as \"Non-Sterile” to indicate its non-processed, and non-sterile status to ensure only medical devices, which have undergone the sterilization process are accepted, and distributed to the US market. Additionally, during the inspection of the off-site EtO Sterilization Facility your firm had multiple pallets of various finished Class II medical devices intended for the US market labeled as \"Sterile\", which had not undergone the sterilization process.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm conducted the following actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provided its revised Product Identification and Traceability Procedure, which your firm states updates the requirements to add labeling to devices to denote sterilization status.\u003C\u002Fli>\n\t\u003Cli>Established a sample management procedure to define how to manage the sample used for registration test, design, and development.\u003C\u002Fli>\n\t\u003Cli>Trained personnel on these procedures and executed sample management control.\u003C\u002Fli>\n\t\u003Cli>Reviewed its other product lines within its facilities to determine if they lacked proper labelling of sterilization status.\u003C\u002Fli>\n\t\u003Cli>Checked raw materials, components, labelling, and finished medical devices throughout its facility to determine if there were other products that lacked sample labeling.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the documents the firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA. Additionally, your firm has not conducted a retrospective review to determine whether unsterilized product was released.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain procedures to control all documents as required by 21 CFR 820.40.\u003C\u002Fp>\n\n\u003Cp>For example: Your firm’s document control procedure, Company Operation Control Procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, has not been adequately established to ensure only approved documents are distributed throughout the facility. Several documents were found within the facility outside of their designated locations. These documents include but are not limited to Internal Quality Audits records, sterilization notice forms, sterilization validation records, sterility test records.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it conducted the following actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Provided its revised Quality Record Procedure, which it has implemented and has retrained its related personnel.\u003C\u002Fli>\n\t\u003Cli>Reviewed its entire facility to ensure that all controlled documents were properly stored in their new designated locations.\u003C\u002Fli>\n\t\u003Cli>Performed a retrospective review of all of its quality records to ensure that they were placed in the correct location.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA. Additionally, your firm did not assess whether the uncontrolled documents may have led to nonconformities.\u003C\u002Fp>\n\n\u003Cp>6. Failure to maintain device history records as required by 820.184.\u003C\u002Fp>\n\n\u003Cp>For example: The device history records (DHRs) did not contain the labeling required by the DHR procedure, Product Batch Record Control Procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it conducted the following actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Retrained its related personnel in its Product Batch Record Control Procedure.\u003C\u002Fli>\n\t\u003Cli>Required that all the DHRs contain the labeling for photographed and printed product carton main mark and side mark.\u003C\u002Fli>\n\t\u003Cli>Retrospectively reviewed all of its DHR reports for all of the products destined for your firm’s U.S. customers.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>For example: During the inspection, your firm acknowledged that its MDR procedure titled “Control Procedure for Issuance and Implementation of Adverse Event”, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, does not contain information indicating that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. The response included a copy of your firm’s revised MDR procedure titled “Control Procedure for Issuance and Implementation of Adverse Event”, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It also includes evidence that personnel were trained and a statement indicating that your firm plans to conduct a retrospective review of its complaints by November 20, 2021. However, the revised MDR procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is written mostly in a foreign language with limited English translated sections. As such, FDA was unable to conduct a full assessment for adequacy of your firm’s MDR procedure. Your firm should provide a complete English translated version of its MDR procedure to the FDA. In addition, there is no evidence your firm’s retrospective review was completed as such actions were ongoing at the time the response was received.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, the Class II Sterile Single Use Disposable Electrodes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 623042 when replying. If you have any questions about the contents of this letter, please contact: Long Chen at (301) 796-6389.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, MD, MBA, FACS\u003Cbr>\nDirector\u003Cbr>\nOffice of Surgery and Infection Control Devices\u003Cbr>\nOffice of Product Quality and Evaluation\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nMr. David Lennarz\u003Cbr>\nRegistrar Corp\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA 23666\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMac Lai\n\nRecipient Title\n\nCEO\n\nWickimed Medical Equipment Manufacturing Co., Ltd.\n\nXingWang Street, LiLin Town\n\nZhongKai Hi-Tech Zone\n\nHuizhou Shi\n\nGuangdong Sheng, 516003\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nJanuary 7, 2022\n\nDear Mr. Lai:\n\nDuring an inspection of your firm located in HuiZhou China, on September 6, 2021 through September 14, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Class II Sterile Single Use Disposable Electrodes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received two response from you dated October 3, 2021 and October 20, 2021 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations.\n\nYour firm’s responses dated November 24, 2021 and December 20, 2021 to the Form FDA 483 (FDA 483) was not reviewed because it was not received within fifteen business days of issuance of the FDA 483. The response will be evaluated along with any other written material provided in response to the violations cited in this Warning Letter. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\n\nFor example: Your firm’s Control Procedures for Customer Feedback, Complaints and Return, (b)(4) and dated (b)(4), has no requirement to ensure your firm is receiving complaints from its distributor that is marketing and selling the private label manufactured medical devices in the US market. Additionally, your firm has no documented agreement with its US private label distributor requiring them to provide your firm with complaints. It is important that your firm reviews and evaluates all complaints in a uniform and timely manner to determine whether an investigation is necessary and that they are evaluated to determine whether the complaint represents an event that is reportable under 21 CFR Part 806, Medical Device Reporting.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm provided their revised Customer Feedback, Complaints, and Returns procedure, which your firm indicates establishes responsibility for complaint handling activities. Your response stated that this included the firm’s need to evaluate complaints to determine if an investigation is necessary and should be reported to the US FDA, for all new and existing customers. Your firm’s response stated it conducted the following actions:\n\nReviewed the FDA MAUDE database for the past 5 years and initiated customer complaints for the 3 MDRs found in order to perform complaint investigations.\n\nRevised its Contract Review Procedures.\n\nProvided training to the related personnel on both revised procedures. Retrospectively reviewed the EUDAMED and NMPA databases and found no complaints relating to your devices.\n\nHowever, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA. Additionally, your response does not reveal if the distributor has been contacted to determine if any complaints have been received.\n\n2. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\n\nFor example: Your firm began sterilization activities for their private label sterile medical devices and contract manufactured medical devices on December 23, 2019. During the inspection, your firm was not able to provide detailed information on the sterilization validation process, nor objective evidence and data.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm acknowledges that it did not retain the raw data to support the report as there was no requirement for handwriting the data in its procedures. Your firm’s response stated that it conducted the following actions:\n\nReviewed its data for sterilization cycle records and were able to determine that there were no Biological Indicator failures for the past 3 years.\n\nReviewed its customer complaints for the past three years to determine whether there were any complaints related to inadequate sterilization process or the sterility of their product.\n\nConducted IQ\u002FOQ revalidation for the sterilization chamber that did not have handwritten data.\n\nProvided its draft Product Registration and Marketing Authorization control procedure.\n\nProvided its Revised Sterilization Process Control procedures.\n\nConducted training on its new procedures.\n\nHowever, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the responses for adequacy. Your firm should provide a complete English translated version of its documents to the FDA.\n\n3. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\n\nFor example: Your firm has not adequately established Design Control procedures related to its line of private label manufactured Sterile Single Use Disposable Electrodes that are exported and intended for the US market. Your firm stated that it was not familiar with or could not provide the following:\n\nIts design and development procedures.\n\nExplain what design and developments activities were conducted and the results.\n\nProvide nor locate all the documentation related to the Class II Sterile Single Use Disposable Electrodes (GEI), DHF and 510(k).\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm conducted the following actions:\n\nProvided its revised Design and Development Management Procedure and trained its related personnel on the revised procedures.\n\nConducted reverification and revalidation on the microneedles.\n\nConducted a retrospective review of its DHF and found some missing objective data and evidence for its Electrosurgical Pencil with Electrode WP 200 Series.\n\nConducted reverification and revalidation on the Electrosurgical Pencil with Electrode WP 200 series.\n\nReviewed your design verification and validation for your other products and determined that the design verification and design validation reports had included objective data and evidence.\n\nHowever, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the responses for adequacy. Your firm should provide a complete English translated version of its documents to the FDA.\n\n4. Failure to identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86.\n\nFor example: Your firm has not established procedures to properly identify medical devices labeled as \"Sterile\", which have not undergone the sterilization process are properly and conspicuously identified as \"Non-Sterile” to indicate its non-processed, and non-sterile status to ensure only medical devices, which have undergone the sterilization process are accepted, and distributed to the US market. Additionally, during the inspection of the off-site EtO Sterilization Facility your firm had multiple pallets of various finished Class II medical devices intended for the US market labeled as \"Sterile\", which had not undergone the sterilization process.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that your firm conducted the following actions:\n\nProvided its revised Product Identification and Traceability Procedure, which your firm states updates the requirements to add labeling to devices to denote sterilization status.\n\nEstablished a sample management procedure to define how to manage the sample used for registration test, design, and development.\n\nTrained personnel on these procedures and executed sample management control.\n\nReviewed its other product lines within its facilities to determine if they lacked proper labelling of sterilization status.\n\nChecked raw materials, components, labelling, and finished medical devices throughout its facility to determine if there were other products that lacked sample labeling.\n\nHowever, the documents the firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA. Additionally, your firm has not conducted a retrospective review to determine whether unsterilized product was released.\n\n5. Failure to establish and maintain procedures to control all documents as required by 21 CFR 820.40.\n\nFor example: Your firm’s document control procedure, Company Operation Control Procedure, (b)(4) and dated (b)(4), has not been adequately established to ensure only approved documents are distributed throughout the facility. Several documents were found within the facility outside of their designated locations. These documents include but are not limited to Internal Quality Audits records, sterilization notice forms, sterilization validation records, sterility test records.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it conducted the following actions:\n\nProvided its revised Quality Record Procedure, which it has implemented and has retrained its related personnel.\n\nReviewed its entire facility to ensure that all controlled documents were properly stored in their new designated locations.\n\nPerformed a retrospective review of all of its quality records to ensure that they were placed in the correct location.\n\nHowever, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA. Additionally, your firm did not assess whether the uncontrolled documents may have led to nonconformities.\n\n6. Failure to maintain device history records as required by 820.184.\n\nFor example: The device history records (DHRs) did not contain the labeling required by the DHR procedure, Product Batch Record Control Procedure, (b)(4) and dated (b)(4).\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s response stated that it conducted the following actions:\n\nRetrained its related personnel in its Product Batch Record Control Procedure.\n\nRequired that all the DHRs contain the labeling for photographed and printed product carton main mark and side mark.\n\nRetrospectively reviewed all of its DHR reports for all of the products destined for your firm’s U.S. customers.\n\nHowever, the documents your firm provided are written mostly in a foreign language with limited English translated sections. Therefore, it is not possible to conduct a full assessment of the response for adequacy. Your firm should provide a complete English translated version of its documents to the FDA.\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nFor example: During the inspection, your firm acknowledged that its MDR procedure titled “Control Procedure for Issuance and Implementation of Adverse Event”, (b)(4), dated (b)(4), does not contain information indicating that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17.\n\nWe reviewed your firm’s response and conclude that it is not adequate. The response included a copy of your firm’s revised MDR procedure titled “Control Procedure for Issuance and Implementation of Adverse Event”, (b)(4), dated (b)(4). It also includes evidence that personnel were trained and a statement indicating that your firm plans to conduct a retrospective review of its complaints by November 20, 2021. However, the revised MDR procedure (b)(4), is written mostly in a foreign language with limited English translated sections. As such, FDA was unable to conduct a full assessment for adequacy of your firm’s MDR procedure. Your firm should provide a complete English translated version of its MDR procedure to the FDA. In addition, there is no evidence your firm’s retrospective review was completed as such actions were ongoing at the time the response was received.\n\nGiven the serious nature of the violations of the Act, the Class II Sterile Single Use Disposable Electrodes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 623042 when replying. If you have any questions about the contents of this letter, please contact: Long Chen at (301) 796-6389.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS\n\nDirector\n\nOffice of Surgery and Infection Control Devices\n\nOffice of Product Quality and Evaluation\n\nCenter for Devices and Radiological Health\n\nCC:\n\nMr. David Lennarz\n\nRegistrar Corp\n\n144 Research Drive\n\nHampton, VA 23666","Wickimed Medical Equipment Manufacturing Co., Ltd.","wickimed-medical-equipment-manufacturing-co-ltd-623042-01072022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwickimed-medical-equipment-manufacturing-co-ltd-623042-01072022","2026-10-26T08:10:31.88356+00:00","2022-03-08","623042","2022-06-02","Mac Lai","2026-08-20T02:07:55.226+00:00","2022-01-07",{"id":246,"raw":247,"subject":251,"body_html":252,"body_text":253,"firm_name":254,"letter_id":255,"created_at":256,"fei_number":20,"letter_url":257,"updated_at":215,"action_type":23,"case_status":24,"posted_date":258,"marcs_cms_no":259,"product_type":66,"closeout_date":20,"issuing_office":55,"recipient_name":260,"body_fetched_at":261,"delivery_method":107,"recipient_title":20,"reference_number":20,"action_taken_date":262,"medical_device_id":20,"response_letter_date":20},21730,[248,249,250,55,251,13,13,13],"\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-21T04:00:00Z\">08\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flion-street-medical-dba-pensar-medical-llc-733015-08212026\">Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason Allen Bandy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer (CEO) \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>109 N Post Oak Ln, Suite 525\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77024-7862\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #733015\u003C\u002Fp>\u003Cp>August 21, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Bandy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Houston, TX from April 14, 2026, through April 28, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm, Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC, manufactures the WoundPro Negative Pressure Wound Therapy (NPWT) System, the WoundPro+ NPWT System, and the MicroDoc (PocketDoc) Portable NPWT System (negative pressure wound therapy systems). These products are intended to promote wound healing by draining and removing infectious material and other fluids from the wound site through continuous and\u002For intermittent negative pressure. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that your firm’s negative pressure wound therapy systems are misbranded under 21 CFR 803.17 in that your firm failed or refused to develop, maintain, and implement written MDR procedures required by or under section 519 of the Act, 21 U.S.C. § 360i. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. During the inspection, your firm presented its MDR procedure titled “Medical Device Reporting”, WI103-01, Rev. 2, dated 12\u002F12\u002F2023. Upon review, we noted the following deficiencies:\u003C\u002Fp>\u003Cp>a) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include a definition of what “reasonably suggests” whether a reportable event has occurred as it is described in 21 CFR 803.20(c)(1); this may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>b) The procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b). The procedure also does not include documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\u003Cp>Your firm’s response dated May 19, 2026, did not address the procedural deficiencies noted above as they were not listed on the Form FDA 483. Your firm’s response dated June 19, 2026, is a periodic update that provides the status of its progress and outlines its plan to address MDR reporting requirements by August 2026.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s negative pressure wound therapy systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>2. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint C-029 reasonably suggests that, while using your firm’s negative pressure wound therapy System, the patient sustained an infection at the wound site (i.e., purulent drainage). Absent additional information regarding the wound location, severity, or your firm’s rationale for determining that the event was not reportable, the available information reasonably suggests that the patient sustained an infection in the treated wound area that necessitated medical or surgical intervention, including removal of the retained foam, to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, the information reasonably suggests that the device associated event represents an MDR-reportable serious injury as defined in 21 CFR 803.3(w). Your firm became aware of the event on May 1, 2024, and FDA has not yet received a serious injury MDR for this adverse event.\u003C\u002Fp>\u003Cp>Your firm’s responses dated May 19, 2026, and June 19, 2026, are inadequate. In these responses, your firm states that it initiated CAPA-045 to implement systemic corrective actions, including a retrospective review, streamlining the MDR reporting process, staff retraining, and submission of the reports through its agent, to address the reporting issue. However, these actions are still ongoing, and the responses do not include documentation demonstrating completion or implementation of these corrective actions.\u003C\u002Fp>\u003Cp>Your firm submitted MDR 3007793449-2024-00001 for the serious injury referenced for Complaint C-029. However, the MDR was incorrectly submitted as a malfunction report. As indicated above, the referenced event meets the definition of a serious injury. Therefore, the corresponding MDR should have identified the event in Block H1 of Form FDA 3500A, Type of Reportable Event, as a Serious Injury (21 CFR 803.52(f)). Accordingly, your firm must submit corrected date for this MDR to correct the error and identify the correct Type of Reportable Event. In addition, as required by 21 CFR 803.3(m)(2), the manufacturer report number must include the four-digit calendar year in which the report was submitted. Going forward, please ensure all initial MDRs use the correct submission year when constructing the manufacturer report number. For MDRs already submitted, this requirement is not applicable to the supplemental reports, and the manufacturer report number should not be changed when submitting the supplements.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated July 20, 2026, and conclude that it is not adequate. In that response, your firm provided the following draft documents:\u003C\u002Fp>\u003Cp>“Customer Complaints and Customer Feedback”, QP103, Revision 03\u003Cbr>“Medical Device Reporting”, WI103-01, Revision 03\u003Cbr>“Customer Complaint Report Form”, FM103-01, Revision 03\u003C\u002Fp>\u003Cp>We collectively reviewed these documents as your firm’s revised MDR procedure and noted that they do not include a definition of the term “reasonably suggests”. In addition, your firm indicated that these draft documents are not expected to be implemented until August 31, 2026.\u003C\u002Fp>\u003Cp>In that response, your firm also provided evidence that it had completed a retrospective review and MDR evaluation of complaints received since October 2023. However, as previously noted, MDR 3007793449-2024-00001 was incorrectly submitted as a malfunction report. Corrected data is required to revise the event type from malfunction to serious injury in Block H1 of the FDA Form 3500A. In addition, please note that, moving forward, the manufacturer report number must include the four-digit calendar year in which the initial report was submitted pursuant to 21 CFR 803.3(m)(2).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s MicroDoc (PocketDoc) Portable NPWT System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report required by 21 CFR 806.10 to FDA within 10 working days of initiating the correction or removal.\u003C\u002Fp>\u003Cp>For example, your firm conducted a correction of your MicroDoc (PocketDoc) Portable NPWT System device software which can lead to an outcome where the probability of adverse health consequences is remote and more likely than not that an event will occur. Your firm conducted software reworks and updates to the newest MicroDoc software for at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> customers who purchased the software with the wrong version and updated Revision B (ECO 25-052) of the MicroDoc Programming Work Instruction (Document # 169378-1001) to reflect the correct software revision to be used. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a report of correction or removal to FDA.\u003C\u002Fp>\u003Cp>Your firm’s responses to the FDA-483, dated May 19, 2026, June 19, 2026, and July 20, 2026, do not address this issue. You have not submitted a report of correction or removal to FDA as of August 20, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality Management System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation (QMSR) found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response dated May 19, 2026, and a follow-up update dated June 19, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\u003C\u002Fp>\u003Cp>For example, your firm failed to document your QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) program across its WoundPro, WoundPro+, and MicroDoc (PocketDoc) device lines. The following specific deficiencies were identified:\u003C\u002Fp>\u003Cp>a) Your Design Failure Mode and Effects Analysis (dFMEA) for the PocketDoc device identifies \u003Cstrong>(b)(4)\u003C\u002Fstrong> distinct hazards. The risk control verification entries associated with software, sterilization, storage, packaging, and exudate management (entries P3, P4, P6, P7, P10, and P24 through P27) are all marked “In Progress,” and the corresponding risk controls had not been implemented and verified at the time of inspection.\u003C\u002Fp>\u003Cp>b) Your firm’s formal QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) requires a user FMEA (uFMEA), design FMEA (dFMEA), and process FMEA (pFMEA) for every product. No WoundPro FMEAs of any type were found to exist.\u003C\u002Fp>\u003Cp>c) Your software-specific dFMEA for the MicroDoc device encompasses \u003Cstrong>(b)(4)\u003C\u002Fstrong> software hazards. Of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> high-risk verification entries, \u003Cstrong>(b)(4)\u003C\u002Fstrong> were recorded as “In Progress” at the time of inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. None of the short-term corrections or corrective actions are complete as of either response date. The WoundPro and MicroDoc FMEAs have critical missing elements, and no interim risk mitigation plan has been described for the period between the inspection and the completion of the FMEAs. The procedure overhaul for six QMS procedures (QP116, QP129, QP106, QP105, QP123, and QP110) has not been finalized, and no FMEA recreation is documented as complete. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of a new Quality Manager, these actions do not constitute a completed corrective action plan. Your targeted completion date for your corrective actions is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and therefore, additionally, your response is not adequate.\u003C\u002Fp>\u003Cp>2. Failure to adequately review, verify, validate, and approve design and development changes before implementation, as required by ISO 13485:2016 Clause 7.3.9.\u003C\u002Fp>\u003Cp>For example, your firm’s change records did not include records of necessary actions, in that your firm approved, implemented, and closed out multiple software changes to the MicroDoc and WoundPro+ devices without records that the changes were correctly, completely, or safely implemented. The following specific deficiencies were identified across eleven Engineering Change Orders (ECOs) reviewed during the inspection:\u003C\u002Fp>\u003Cp>a) ECO 25-039 (effective June 23, 2025) documents a WoundPro+ firmware update from revision \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\u003C\u002Fp>\u003Cp>b) ECO 25-033 (effective May 20, 2025) documents an earlier WoundPro+ firmware update from revision \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\u003C\u002Fp>\u003Cp>c) ECO 25-022 (effective April 15, 2025), ECO 25-021 (effective March 11, 2025, p. 93), ECO 25-008 (effective March 4, 2025, p. 94), ECO 24-040 (effective November 21, 2024, p. 95), ECO 24-030 (effective September 20, 2024, p. 96), and ECO 24-024 (effective August 15, 2024, pp. 97–98) each document firmware or software changes that took effect at specific serial number thresholds without any batch record or other record provided upon request to confirm implementation. For ECO 25-008 (“clean up all code,” revision \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), neither your CEO nor your President could explain what code changes were actually incorporated, and no verification record exists.\u003C\u002Fp>\u003Cp>d) Your Software Validation Procedure (QP123, Rev 02) states that revalidation is required when there is a significant change and lists software updates among the triggers for revalidation. However, your procedure does not address the need to confirm that unchanged but potentially affected portions of the software have not been inadvertently disrupted by a change, leaving a systematic gap in your firm’s ability to detect regression failures.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026, and conclude that they are not adequate. With respect to ECO 25-039 (WoundPro+ firmware update to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your July 17, 2026 Memo to ECO Files references the batch traveler for serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the batch traveler, Final QC Inspection Sheet, and Final Acceptance Test Data Sheet submitted with the July 20, 2026 update. However, the memo acknowledges that the hold on ECO 25-033 was communicated verbally only, with no nonconformance report (NCR) or formal documentation generated, and this procedural gap remains unresolved. Furthermore, no documented formal risk assessment has been submitted for ECO 25-039, and your characterization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> noise change as “cosmetic in nature” and unrelated to “safety or effectiveness” continues to be made without a documented risk assessment tied to the device’s design FMEA. Your procedure revisions to QP129, QP106, and QP123, targeted for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, remain incomplete, the retrospective ECO review for all remaining ECOs has not been documented as complete, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing gap in QP123 has not been resolved.\u003C\u002Fp>\u003Cp>3. Failure to document an adequate procedure to define requirements for corrective action, as required ISO 13485:2016 Clause 8.5.2.\u003C\u002Fp>\u003Cp>For example, your “Corrective and Preventive Action” procedure (QP110, Rev 01, 04\u002F14\u002F2026) requires documentation of root causes, corrective action plans, and verified effectiveness before any CAPA record can be closed. The procedure requires these activities be documented on Form110-01, Corrective and Preventive Action (CAPA) Form. A review of five CAPA records revealed a pattern of blank root cause fields, missing corrective actions, and unverified effectiveness across all five records, in direct violation of your firm’s own established procedure:\u003C\u002Fp>\u003Cp>a) CAPA-031, 2\u002F22\u002F23, was opened in response to identified deficiencies in CAPA documentation. The record was closed without any corrective actions, preventive actions, or effectiveness verification having been documented.\u003Cbr>b) CAPA-036, 1\u002F9\u002F2024 &amp; 1\u002F19\u002F2024 reflects that corrective action was taken; however, that action was never incorporated into your firm’s risk analysis, and the fields designated for effectiveness verification were left blank.\u003Cbr>c) CAPA-037, 1\u002F9\u002F2024 is entirely incomplete. The root cause section, the corrective and preventive action sections, and the effectiveness verification section are all blank. No substantive documentation was entered into this record.\u003Cbr>d) CAPA-039, 1\u002F19\u002F2024 shows a blank root cause field, no documented corrective actions, and effectiveness sections containing only unfilled placeholder language carried over from the template.\u003Cbr>e) CAPA-040, 10\u002F25\u002F2024 shows blank root cause fields, incomplete corrective action entries, and no documented effectiveness verification.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. Issuing Memos to File to update five CAPA records to “Ineffective” status acknowledges the problem but does not constitute corrective action. None of the short-term corrections for this observation are complete as of the June 19, 2026 update. The QP110 overhaul has not been finalized. Furthermore, all seven new CAPAs (CAPA-041 through CAPA-047) opened in response to this inspection continue to be managed under the same underdefined procedure that was cited as deficient. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of Quality Manager \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, these actions do not constitute completed corrective action. In addition, no completion dates are entered in your Quality Plan for any CAPA-047 action items.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at CDRHEnforcement@fda.hhs.gov Please include in the subject line, CMS Case #733015, when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo, Compliance Officer, at Raymond.Brullo@fda.hhs.gov\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>For Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJason Allen Bandy\n\nRecipient Title\n\nChief Executive Officer (CEO)\n\nLion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC\n\n109 N Post Oak Ln, Suite 525\n\nHouston, TX 77024-7862\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #733015\nAugust 21, 2026\nDear Mr. Bandy:\nDuring an inspection of your firm located in Houston, TX from April 14, 2026, through April 28, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm, Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC, manufactures the WoundPro Negative Pressure Wound Therapy (NPWT) System, the WoundPro+ NPWT System, and the MicroDoc (PocketDoc) Portable NPWT System (negative pressure wound therapy systems). These products are intended to promote wound healing by draining and removing infectious material and other fluids from the wound site through continuous and\u002For intermittent negative pressure. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nMedical Device Reporting (MDR) Violations\nOur inspection revealed that your firm’s negative pressure wound therapy systems are misbranded under 21 CFR 803.17 in that your firm failed or refused to develop, maintain, and implement written MDR procedures required by or under section 519 of the Act, 21 U.S.C. § 360i. Significant violations include, but are not limited to, the following:\n1. During the inspection, your firm presented its MDR procedure titled “Medical Device Reporting”, WI103-01, Rev. 2, dated 12\u002F12\u002F2023. Upon review, we noted the following deficiencies:\na) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include a definition of what “reasonably suggests” whether a reportable event has occurred as it is described in 21 CFR 803.20(c)(1); this may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb) The procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b). The procedure also does not include documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\nYour firm’s response dated May 19, 2026, did not address the procedural deficiencies noted above as they were not listed on the Form FDA 483. Your firm’s response dated June 19, 2026, is a periodic update that provides the status of its progress and outlines its plan to address MDR reporting requirements by August 2026.\nOur inspection also revealed that your firm’s negative pressure wound therapy systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n2. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint C-029 reasonably suggests that, while using your firm’s negative pressure wound therapy System, the patient sustained an infection at the wound site (i.e., purulent drainage). Absent additional information regarding the wound location, severity, or your firm’s rationale for determining that the event was not reportable, the available information reasonably suggests that the patient sustained an infection in the treated wound area that necessitated medical or surgical intervention, including removal of the retained foam, to preclude permanent impairment of a body function or permanent damage to a body structure. Therefore, the information reasonably suggests that the device associated event represents an MDR-reportable serious injury as defined in 21 CFR 803.3(w). Your firm became aware of the event on May 1, 2024, and FDA has not yet received a serious injury MDR for this adverse event.\nYour firm’s responses dated May 19, 2026, and June 19, 2026, are inadequate. In these responses, your firm states that it initiated CAPA-045 to implement systemic corrective actions, including a retrospective review, streamlining the MDR reporting process, staff retraining, and submission of the reports through its agent, to address the reporting issue. However, these actions are still ongoing, and the responses do not include documentation demonstrating completion or implementation of these corrective actions.\nYour firm submitted MDR 3007793449-2024-00001 for the serious injury referenced for Complaint C-029. However, the MDR was incorrectly submitted as a malfunction report. As indicated above, the referenced event meets the definition of a serious injury. Therefore, the corresponding MDR should have identified the event in Block H1 of Form FDA 3500A, Type of Reportable Event, as a Serious Injury (21 CFR 803.52(f)). Accordingly, your firm must submit corrected date for this MDR to correct the error and identify the correct Type of Reportable Event. In addition, as required by 21 CFR 803.3(m)(2), the manufacturer report number must include the four-digit calendar year in which the report was submitted. Going forward, please ensure all initial MDRs use the correct submission year when constructing the manufacturer report number. For MDRs already submitted, this requirement is not applicable to the supplemental reports, and the manufacturer report number should not be changed when submitting the supplements.\nWe reviewed your firm’s response dated July 20, 2026, and conclude that it is not adequate. In that response, your firm provided the following draft documents:\n“Customer Complaints and Customer Feedback”, QP103, Revision 03\n“Medical Device Reporting”, WI103-01, Revision 03\n“Customer Complaint Report Form”, FM103-01, Revision 03\nWe collectively reviewed these documents as your firm’s revised MDR procedure and noted that they do not include a definition of the term “reasonably suggests”. In addition, your firm indicated that these draft documents are not expected to be implemented until August 31, 2026.\nIn that response, your firm also provided evidence that it had completed a retrospective review and MDR evaluation of complaints received since October 2023. However, as previously noted, MDR 3007793449-2024-00001 was incorrectly submitted as a malfunction report. Corrected data is required to revise the event type from malfunction to serious injury in Block H1 of the FDA Form 3500A. In addition, please note that, moving forward, the manufacturer report number must include the four-digit calendar year in which the initial report was submitted pursuant to 21 CFR 803.3(m)(2).\nCorrections and Removals Violations\nOur inspection also revealed that your firm’s MicroDoc (PocketDoc) Portable NPWT System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit a report required by 21 CFR 806.10 to FDA within 10 working days of initiating the correction or removal.\nFor example, your firm conducted a correction of your MicroDoc (PocketDoc) Portable NPWT System device software which can lead to an outcome where the probability of adverse health consequences is remote and more likely than not that an event will occur. Your firm conducted software reworks and updates to the newest MicroDoc software for at least (b)(4) customers who purchased the software with the wrong version and updated Revision B (ECO 25-052) of the MicroDoc Programming Work Instruction (Document # 169378-1001) to reflect the correct software revision to be used. This action is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a report of correction or removal to FDA.\nYour firm’s responses to the FDA-483, dated May 19, 2026, June 19, 2026, and July 20, 2026, do not address this issue. You have not submitted a report of correction or removal to FDA as of August 20, 2026.\nQuality Management System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation (QMSR) found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response dated May 19, 2026, and a follow-up update dated June 19, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\nFor example, your firm failed to document your QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) program across its WoundPro, WoundPro+, and MicroDoc (PocketDoc) device lines. The following specific deficiencies were identified:\na) Your Design Failure Mode and Effects Analysis (dFMEA) for the PocketDoc device identifies (b)(4) distinct hazards. The risk control verification entries associated with software, sterilization, storage, packaging, and exudate management (entries P3, P4, P6, P7, P10, and P24 through P27) are all marked “In Progress,” and the corresponding risk controls had not been implemented and verified at the time of inspection.\nb) Your firm’s formal QMS Process Risk Management (QP116, Rev. 01, 04\u002F24\u002F2026) requires a user FMEA (uFMEA), design FMEA (dFMEA), and process FMEA (pFMEA) for every product. No WoundPro FMEAs of any type were found to exist.\nc) Your software-specific dFMEA for the MicroDoc device encompasses (b)(4) software hazards. Of the (b)(4) high-risk verification entries, (b)(4) were recorded as “In Progress” at the time of inspection.\nWe reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. None of the short-term corrections or corrective actions are complete as of either response date. The WoundPro and MicroDoc FMEAs have critical missing elements, and no interim risk mitigation plan has been described for the period between the inspection and the completion of the FMEAs. The procedure overhaul for six QMS procedures (QP116, QP129, QP106, QP105, QP123, and QP110) has not been finalized, and no FMEA recreation is documented as complete. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of a new Quality Manager, these actions do not constitute a completed corrective action plan. Your targeted completion date for your corrective actions is (b)(4) and therefore, additionally, your response is not adequate.\n2. Failure to adequately review, verify, validate, and approve design and development changes before implementation, as required by ISO 13485:2016 Clause 7.3.9.\nFor example, your firm’s change records did not include records of necessary actions, in that your firm approved, implemented, and closed out multiple software changes to the MicroDoc and WoundPro+ devices without records that the changes were correctly, completely, or safely implemented. The following specific deficiencies were identified across eleven Engineering Change Orders (ECOs) reviewed during the inspection:\na) ECO 25-039 (effective June 23, 2025) documents a WoundPro+ firmware update from revision (b)(4) to (b)(4). No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\nb) ECO 25-033 (effective May 20, 2025) documents an earlier WoundPro+ firmware update from revision (b)(4) to (b)(4). No batch record or other record demonstrating implementation of this change was provided upon request to confirm the update was implemented. Your firm’s President confirmed during the inspection that no such batch record had been documented.\nc) ECO 25-022 (effective April 15, 2025), ECO 25-021 (effective March 11, 2025, p. 93), ECO 25-008 (effective March 4, 2025, p. 94), ECO 24-040 (effective November 21, 2024, p. 95), ECO 24-030 (effective September 20, 2024, p. 96), and ECO 24-024 (effective August 15, 2024, pp. 97–98) each document firmware or software changes that took effect at specific serial number thresholds without any batch record or other record provided upon request to confirm implementation. For ECO 25-008 (“clean up all code,” revision (b)(4) to (b)(4)), neither your CEO nor your President could explain what code changes were actually incorporated, and no verification record exists.\nd) Your Software Validation Procedure (QP123, Rev 02) states that revalidation is required when there is a significant change and lists software updates among the triggers for revalidation. However, your procedure does not address the need to confirm that unchanged but potentially affected portions of the software have not been inadvertently disrupted by a change, leaving a systematic gap in your firm’s ability to detect regression failures.\nWe reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026, and conclude that they are not adequate. With respect to ECO 25-039 (WoundPro+ firmware update to (b)(4)), your July 17, 2026 Memo to ECO Files references the batch traveler for serial number (b)(4), and the batch traveler, Final QC Inspection Sheet, and Final Acceptance Test Data Sheet submitted with the July 20, 2026 update. However, the memo acknowledges that the hold on ECO 25-033 was communicated verbally only, with no nonconformance report (NCR) or formal documentation generated, and this procedural gap remains unresolved. Furthermore, no documented formal risk assessment has been submitted for ECO 25-039, and your characterization of the (b)(4) noise change as “cosmetic in nature” and unrelated to “safety or effectiveness” continues to be made without a documented risk assessment tied to the device’s design FMEA. Your procedure revisions to QP129, QP106, and QP123, targeted for (b)(4), remain incomplete, the retrospective ECO review for all remaining ECOs has not been documented as complete, and the (b)(4) testing gap in QP123 has not been resolved.\n3. Failure to document an adequate procedure to define requirements for corrective action, as required ISO 13485:2016 Clause 8.5.2.\nFor example, your “Corrective and Preventive Action” procedure (QP110, Rev 01, 04\u002F14\u002F2026) requires documentation of root causes, corrective action plans, and verified effectiveness before any CAPA record can be closed. The procedure requires these activities be documented on Form110-01, Corrective and Preventive Action (CAPA) Form. A review of five CAPA records revealed a pattern of blank root cause fields, missing corrective actions, and unverified effectiveness across all five records, in direct violation of your firm’s own established procedure:\na) CAPA-031, 2\u002F22\u002F23, was opened in response to identified deficiencies in CAPA documentation. The record was closed without any corrective actions, preventive actions, or effectiveness verification having been documented.\nb) CAPA-036, 1\u002F9\u002F2024 & 1\u002F19\u002F2024 reflects that corrective action was taken; however, that action was never incorporated into your firm’s risk analysis, and the fields designated for effectiveness verification were left blank.\nc) CAPA-037, 1\u002F9\u002F2024 is entirely incomplete. The root cause section, the corrective and preventive action sections, and the effectiveness verification section are all blank. No substantive documentation was entered into this record.\nd) CAPA-039, 1\u002F19\u002F2024 shows a blank root cause field, no documented corrective actions, and effectiveness sections containing only unfilled placeholder language carried over from the template.\ne) CAPA-040, 10\u002F25\u002F2024 shows blank root cause fields, incomplete corrective action entries, and no documented effectiveness verification.\nWe reviewed your firm’s responses dated May 19, 2026, June 19, 2026, and July 20, 2026 and conclude that they are not adequate. Issuing Memos to File to update five CAPA records to “Ineffective” status acknowledges the problem but does not constitute corrective action. None of the short-term corrections for this observation are complete as of the June 19, 2026 update. The QP110 overhaul has not been finalized. Furthermore, all seven new CAPAs (CAPA-041 through CAPA-047) opened in response to this inspection continue to be managed under the same underdefined procedure that was cited as deficient. While we acknowledge receipt of Quality Plan QP 2026-01 (Rev A) and the onboarding of Quality Manager (b)(6), (b)(7)(C), these actions do not constitute completed corrective action. In addition, no completion dates are entered in your Quality Plan for any CAPA-047 action items.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at CDRHEnforcement@fda.hhs.gov Please include in the subject line, CMS Case #733015, when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo, Compliance Officer, at Raymond.Brullo@fda.hhs.gov\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nFor Barbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Lion Street Medical, d\u002Fb\u002Fa Pensar Medical LLC","lion-street-medical-dba-pensar-medical-llc-733015-08212026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flion-street-medical-dba-pensar-medical-llc-733015-08212026","2026-09-22","733015","Jason Allen Bandy","2026-10-14T12:36:33.26+00:00","2026-08-21",{"id":264,"raw":265,"subject":93,"body_html":271,"body_text":272,"firm_name":273,"letter_id":274,"created_at":275,"fei_number":20,"letter_url":276,"updated_at":277,"action_type":23,"case_status":101,"posted_date":278,"marcs_cms_no":279,"product_type":27,"closeout_date":280,"issuing_office":269,"recipient_name":281,"body_fetched_at":282,"delivery_method":283,"recipient_title":20,"reference_number":20,"action_taken_date":284,"medical_device_id":20,"response_letter_date":20},3024,[266,267,268,269,93,13,270,13],"\u003Ctime datetime=\"2021-11-16T14:20:00Z\">11\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-10T05:00:00Z\">11\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021\">Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fa>","Division of Pharmaceutical Quality Operations Division III","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-02242026\">\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leonard D. Guyer, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>836 E. 86th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indianapolis\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46240-1806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations Division III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL # 615908\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 10, 2021\u003Cbr>\n\u003Cbr>\nDear Dr. Guyer:\u003C\u002Fp>\n\n\u003Cp>From October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503A\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\u003C\u002Fp>\n\n\u003Cp>1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products, including Energy Boost.\u003C\u002Fp>\n\n\u003Cp>2. Your firm compounded drug products using \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Drug products compounded using \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not eligible for the exemptions provided by section 503A(a), because \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Therefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\u003C\u002Fp>\n\n\u003Cp>2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\u003C\u002Fp>\n\n\u003Cp>3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\u003Cbr>\n&nbsp; a. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\u003Cbr>\n&nbsp; b. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\u003Cbr>\n&nbsp; c. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\u003C\u002Fp>\n\n\u003Cp>6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\u003C\u002Fp>\n\n\u003Cp>7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\u003C\u002Fp>\n\n\u003Cp>8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Moreover, your firm’s temperature and time conditions used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials are not known to be \u003Cstrong>(b)(4)\u003C\u002Fstrong> microorganisms.\u003C\u002Fp>\n\n\u003Cp>9. Your firm has not conducted environmental monitoring since 2018.\u003C\u002Fp>\n\n\u003Cp>10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\u003Cbr>\n&nbsp; a. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\u003Cbr>\n&nbsp; b. Your ISO 5 cleanroom workbench was constructed of laminated wood.\u003Cbr>\n&nbsp; c. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\u003C\u002Fp>\n\n\u003Cp>11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\n\n\u003Cp>7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for the ineligible drug products that you compounded.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\u003C\u002Fp>\n\n\u003Cp>1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\u003C\u002Fp>\n\n\u003Cp>2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\u003C\u002Fp>\n\n\u003Cp>3. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but no further details about the kits were provided. It cannot be determined from the available information if the kits \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>4. Your response states you intend \u003Cstrong>(b)(4)\u003C\u002Fstrong> building which will include \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\u003C\u002Fp>\n\n\u003Cp>5. Your response states your firm has implemented several corrections such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>6. Your response states that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but intend to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, no information was provided about the type of equipment and proposed timeline for this corrective action.\u003C\u002Fp>\n\n\u003Cp>7. Your response states that you would \u003Cstrong>(b)(4)\u003C\u002Fstrong> which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to \u003Cstrong>(b)(4)\u003C\u002Fstrong> to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on laminar airflow.\u003C\u002Fp>\n\n\u003Cp>If outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\u003C\u002Fp>\n\n\u003Cp>8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\u003C\u002Fp>\n\n\u003Cp>9. Your response refers to staff members responsible for administering IVs being allowed to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You did not address certain observations related to insanitary conditions, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\u003C\u002Fp>\n\n\u003Cp>2. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> units to be installed but does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring in your current classified areas.\u003C\u002Fp>\n\n\u003Cp>3. Your response did not address the lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by your operators during aseptic production.\u003C\u002Fp>\n\n\u003Cp>4. Your response failed to address your lack of routine environmental monitoring.\u003C\u002Fp>\n\n\u003Cp>5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\u003C\u002Fp>\n\n\u003Cp>6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that opened vials will \u003Cstrong>(b)(4)\u003C\u002Fstrong> from opening or the date of expiry and the vials will only be \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response did not provide justification for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with or without use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are stored outside of an ISO 5 environment.\u003Cbr>\n\u003Cbr>\n2. Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product vials; however, your response states you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which would not be suitable for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear whether your firm has purchased \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterilization of the product vials. Your response does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials. You provided no information demonstrating that the current \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle is adequate. Your response does not address the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> during sterilization or \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of vials that have not been adequately \u003Cstrong>(b)(4)\u003C\u002Fstrong>, even if adequately sterilized \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not an acceptable practice.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\u003C\u002Fp>\n\n\u003Cp>Furthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&amp;C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. \u003Cem>See\u003C\u002Fem> \u003Cem>Notice to Compounders: Changes that affect compounding as of March 23, 2020\u003C\u002Fem>\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>Lastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>If you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 9, 2016, FDA issued a final guidance titled, \u003Cem>Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fem>. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeonard D. Guyer, MD\n\nRecipient Title\n\nFounder and Medical Director\n\nAdvanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\n\n836 E. 86th Street\n\nIndianapolis, IN 46240-1806\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations Division III\n\nUnited States\n\nWARNING LETTER\n\nWL # 615908\n\nNovember 10, 2021\n\nDear Dr. Guyer:\n\nFrom October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\n\nB. Failure to Meet the Conditions of Section 503A\n\nDuring the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\n\n1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “(b)(4)” products, including Energy Boost.\n\n2. Your firm compounded drug products using (b)(4). Drug products compounded using (b)(4), and (b)(4) are not eligible for the exemptions provided by section 503A(a), because (b)(4), and (b)(4) are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.2\n\nTherefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\n\n2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\n\n3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\n4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\n\n5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\n\na. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\n\nb. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\n\nc. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\n\n6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\n\n7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\n\n8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not (b)(4). Moreover, your firm’s temperature and time conditions used for (b)(4) of product vials are not known to be (b)(4) microorganisms.\n\n9. Your firm has not conducted environmental monitoring since 2018.\n\n10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\n\na. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\n\nb. Your ISO 5 cleanroom workbench was constructed of laminated wood.\n\nc. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\n\n11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\nFurthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\n2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\n\n3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\n\n4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\n\n6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\n7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\n\n8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for the ineligible drug products that you compounded.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nThe ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.4 Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\n\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\n\n1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\n\n2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\n\n3. Your response states that (b)(4), but no further details about the kits were provided. It cannot be determined from the available information if the kits (b)(4).\n\n4. Your response states you intend (b)(4) building which will include (b)(4). No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\n\n5. Your response states your firm has implemented several corrections such as the (b)(4), and (b)(4). No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are (b)(4).\n\n6. Your response states that you plan to (b)(4), but intend to (b)(4). However, no information was provided about the type of equipment and proposed timeline for this corrective action.\n\n7. Your response states that you would (b)(4) which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to (b)(4) to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the (b)(4) on laminar airflow.\n\nIf outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\n\n8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\n\n9. Your response refers to staff members responsible for administering IVs being allowed to (b)(4). It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting (b)(4).\n\nYou did not address certain observations related to insanitary conditions, for example:\n\n1. Your response states that (b)(4) building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\n\n2. Your response states that (b)(4) units to be installed but does not address the (b)(4) monitoring in your current classified areas.\n\n3. Your response did not address the lack of (b)(4) by your operators during aseptic production.\n\n4. Your response failed to address your lack of routine environmental monitoring.\n\n5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\n\n6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\n\nRegarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\n\n1. Your response states that opened vials will (b)(4) from opening or the date of expiry and the vials will only be (b)(4). Your response did not provide justification for (b)(4). It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for (b)(4). Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of (b)(4) vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when (b)(4), with or without use of (b)(4), are stored outside of an ISO 5 environment.\n\n2. Your firm uses (b)(4) drug product vials; however, your response states you are (b)(4), which would not be suitable for use in (b)(4). It is unclear whether your firm has purchased (b)(4) for sterilization of the product vials. Your response does not address the (b)(4) of product vials. You provided no information demonstrating that the current (b)(4) cycle is adequate. Your response does not address the use of (b)(4) during sterilization or (b)(4) during (b)(4). The use of vials that have not been adequately (b)(4), even if adequately sterilized (b)(4), is not an acceptable practice.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.5\n\nIn addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\n\nFurthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. See Notice to Compounders: Changes that affect compounding as of March 23, 20206 and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload).\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\n\nFDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nLastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996).\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nIf you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\n\nYour written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III\n\n______________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n2 On June 9, 2016, FDA issued a final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf.\n\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\n\n4 Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n5 In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\n\n6 Available at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020.","Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine","advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","2026-10-26T08:07:50.520086+00:00","2021-11-16","615908","2026-03-17","Leonard D. Guyer, MD","2026-08-20T02:26:18.165+00:00","UPS Next Day","2021-11-10",15,{"510k":287,"classification":288,"enforcement":289,"event":290,"event_backfill":291,"pma":292,"warning_letter":293},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]